Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    A multi-center, open-label study to investigate the efficacy and safety of CDP870 in active Crohn’s disease patients, who showed no clinical efficacy in a remission induction study (Study CDP870-037) but showed clinical efficacy after additional remission induction therapy was applied, at Week 26 after subcutaneous administration of CDP870 400mg from Week 8 until Week 24 at 4-week intervals

    Summary
    EudraCT number
    		 2014-004400-30
    Trial protocol
    		 Outside EU/EEA  
    Global end of trial date
    11 May 2008

    Results information
    Results version number
    		 v1(current)
    This version publication date
    28 Jun 2016
    First version publication date
    10 Jul 2015
    Other versions

    Trial information

    		 Close Top of page
    Trial identification
    Sponsor protocol code
    C87048
    Additional study identifiers
    ISRCTN number
    		 -
    US NCT number
    		 NCT00329420
    WHO universal trial number (UTN)
    		 -
    Sponsors
    Sponsor organisation name
    UCB Japan Co., Ltd.
    Sponsor organisation address
    2-2 Kanda Surugadai, Tokyo, Japan, 101-0062
    Public contact
    Clinical Trial Registries and Results Disclosure, UCB BIOSCIENCES GmbH, +49 2173 4815 15, clinicaltrials@ucb.com
    Scientific contact
    Clinical Trial Registries and Results Disclosure, UCB BIOSCIENCES GmbH, +49 2173 48 15 15, clinicaltrials@ucb.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    Yes
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    27 Aug 2008
    Is this the analysis of the primary completion data?
    No
    Global end of trial reached?
    Yes
    Global end of trial date
    11 May 2008
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    The primary objective of the study was to evaluate the efficacy of certolizumab pegol 400mg in subjects with active CD who were non-responders in the induction study (Study CDP870-037), but who responded to a second induction with certolizumab pegol. Subjects underwent re-induction with certolizumab pegol 400mg administered every 2 weeks for 3 doses; subjects who responded to the second induction received certolizumab pegol 400mg administered every 4 weeks for 5 doses.
    Protection of trial subjects
    Not applicable
    Background therapy
    		 Not applicable
    Evidence for comparator
    		 Not applicable
    Actual start date of recruitment
    02 May 2006
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    No
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Japan: 46
    Worldwide total number of subjects
    46
    EEA total number of subjects
    0
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    1
    Adults (18-64 years)
    45
    From 65 to 84 years
    0
    85 years and over
    0

    Subject disposition

    		 Close Top of page
    Recruitment
    Recruitment details
    		 Non-responders at Week 6 of the double-blind main study, C87037 (2014-004399-42) could enter this single-group open-label extension study, C87048 (2014-004400-30). Recruitment into this extension study was between May 2006 and May 2008. Of the 26 hospitals in the main study C87037 16 sites went on to enter subjects into this extension study.

    Pre-assignment
    Screening details
    		 Subjects who responded to re-induction (Week 14 visit) in this extension study could enter the 4-weekly dosing phase. Efficacy data are based on these 26 subjects. However, adverse event data are based on all 46 subjects who entered this extension study. Data are presented by the three possible treatment sequences received across both studies.

    Period 1
    Period 1 title
    Study Overall (overall period)
    Is this the baseline period?
    		 Yes
    Allocation method
    Not applicable
    Blinding used
    		 Not blinded

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    		 CZP 400 mg / Placebo
    Arm description
    		 Certolizumab pegol (CZP) 400 mg (3 doses 2-weekly then 5 doses 4-weekly) in this extension study / Placebo (3 doses 2-weekly) in the 6-week double-blind main study (2014-004399-42)
    Arm type
    		 Experimental

    Investigational medicinal product name
    Placebo
    Investigational medicinal product code
    Placebo
    Other name
    Pharmaceutical forms
    Solution for injection in pre-filled syringe
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    Certolizumab pegol (CZP)400 mg (3 doses 2-weekly then 5 doses 4-weekly) in this extension study / Placebo (3 doses 2-weekly) in the 6-week double-blind main study (2014-004399-42)

    Investigational medicinal product name
    Certolizumab pegol
    Investigational medicinal product code
    Certolizumab pegol CZP
    Other name
    Pharmaceutical forms
    Solution for injection in pre-filled syringe
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    Certolizumab pegol (CZP)400 mg (3 doses 2-weekly then 5 doses 4-weekly) in this extension study / Placebo (3 doses 2-weekly) in the 6-week double-blind main study (2014-004399-42) Certolizumab pegol (CZP)400 mg (3 doses 2-weekly then 5 doses 4-weekly) in this extension study / Certolizumab pegol (CZP) 200 mg (3 doses 2-weekly) in the 6-week double-blind main study (2014-004399-42) Certolizumab pegol (CZP) 400 mg (3 doses 2-weekly then 5 doses 4-weekly) in this extension study / Certolizumab pegol (CZP) 400 mg (3 doses 2-weekly) in the 6-week double-blind main study (2014-004399-42)

    Arm title
    		 CZP 400 mg / CZP 200 mg
    Arm description
    		 Certolizumab pegol (CZP) 400 mg (3 doses 2-weekly then 5 doses 4-weekly) in this extension study / Certolizumab pegol (CZP) 200 mg (3 doses 2-weekly) in the 6-week double-blind main study (2014-004399-42)
    Arm type
    		 Experimental

    Investigational medicinal product name
    Certolizumab pegol
    Investigational medicinal product code
    Certolizumab pegol CZP
    Other name
    Pharmaceutical forms
    Solution for injection in pre-filled syringe
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    Certolizumab pegol (CZP)400 mg (3 doses 2-weekly then 5 doses 4-weekly) in this extension study / Placebo (3 doses 2-weekly) in the 6-week double-blind main study (2014-004399-42) Certolizumab pegol (CZP)400 mg (3 doses 2-weekly then 5 doses 4-weekly) in this extension study / Certolizumab pegol (CZP) 200 mg (3 doses 2-weekly) in the 6-week double-blind main study (2014-004399-42) Certolizumab pegol (CZP) 400 mg (3 doses 2-weekly then 5 doses 4-weekly) in this extension study / Certolizumab pegol (CZP) 400 mg (3 doses 2-weekly) in the 6-week double-blind main study (2014-004399-42)

    Arm title
    		 CZP 400 mg / CZP 400 mg
    Arm description
    		 Certolizumab pegol (CZP) 400 mg (3 doses 2-weekly then 5 doses 4-weekly) in this extension study / Certolizumab pegol (CZP) 400 mg (3 doses 2-weekly) in the 6-week double-blind main study (2014-004399-42)
    Arm type
    		 Experimental

    Investigational medicinal product name
    Certolizumab pegol
    Investigational medicinal product code
    Certolizumab pegol CZP
    Other name
    Pharmaceutical forms
    Solution for injection in pre-filled syringe
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    Certolizumab pegol (CZP)400 mg (3 doses 2-weekly then 5 doses 4-weekly) in this extension study / Placebo (3 doses 2-weekly) in the 6-week double-blind main study (2014-004399-42) Certolizumab pegol (CZP)400 mg (3 doses 2-weekly then 5 doses 4-weekly) in this extension study / Certolizumab pegol (CZP) 200 mg (3 doses 2-weekly) in the 6-week double-blind main study (2014-004399-42) Certolizumab pegol (CZP) 400 mg (3 doses 2-weekly then 5 doses 4-weekly) in this extension study / Certolizumab pegol (CZP) 400 mg (3 doses 2-weekly) in the 6-week double-blind main study (2014-004399-42)

    Number of subjects in period 1
    		CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Started
    18
    13
    15
    Moved to maintenance period
    12
    7
    7
    Completed
    8
    5
    6
    Not completed
    10
    8
    9
         Withdrawal of Consent
    1
    -
    1
         Did not respond to re-induction
    3
    5
    4
         AE, non-serious non-fatal
    2
    -
    1
         SAE, non-fatal
    1
    1
    2
         Lack of efficacy
    3
    2
    1

    Baseline characteristics

    		 Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    CZP 400 mg / Placebo
    Reporting group description
    		 Certolizumab pegol (CZP) 400 mg (3 doses 2-weekly then 5 doses 4-weekly) in this extension study / Placebo (3 doses 2-weekly) in the 6-week double-blind main study (2014-004399-42)

    Reporting group title
    CZP 400 mg / CZP 200 mg
    Reporting group description
    		 Certolizumab pegol (CZP) 400 mg (3 doses 2-weekly then 5 doses 4-weekly) in this extension study / Certolizumab pegol (CZP) 200 mg (3 doses 2-weekly) in the 6-week double-blind main study (2014-004399-42)

    Reporting group title
    CZP 400 mg / CZP 400 mg
    Reporting group description
    		 Certolizumab pegol (CZP) 400 mg (3 doses 2-weekly then 5 doses 4-weekly) in this extension study / Certolizumab pegol (CZP) 400 mg (3 doses 2-weekly) in the 6-week double-blind main study (2014-004399-42)

    Reporting group values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg Total
    Number of subjects
    		 18 13 15 46
    Age Categorical
    Units: Subjects
        <=18 years
    		 1 0 0 1
        Between 18 and 65 years
    		 17 13 15 45
        >=65 years
    		 0 0 0 0
    Age Continuous
    Units: years
        arithmetic mean (standard deviation)
    		 30.4 ( 7.5 ) 37.5 ( 8.2 ) 29.9 ( 5.9 ) -
    Gender Categorical
    Units: Subjects
        Female
    		 4 4 3 11
        Male
    		 14 9 12 35
    Region of Enrollment
    Units: Subjects
        Japan
    		 18 13 15 46

    End points

    		 Close Top of page
    End points reporting groups
    Reporting group title
    CZP 400 mg / Placebo
    Reporting group description
    		 Certolizumab pegol (CZP) 400 mg (3 doses 2-weekly then 5 doses 4-weekly) in this extension study / Placebo (3 doses 2-weekly) in the 6-week double-blind main study (2014-004399-42)

    Reporting group title
    CZP 400 mg / CZP 200 mg
    Reporting group description
    		 Certolizumab pegol (CZP) 400 mg (3 doses 2-weekly then 5 doses 4-weekly) in this extension study / Certolizumab pegol (CZP) 200 mg (3 doses 2-weekly) in the 6-week double-blind main study (2014-004399-42)

    Reporting group title
    CZP 400 mg / CZP 400 mg
    Reporting group description
    		 Certolizumab pegol (CZP) 400 mg (3 doses 2-weekly then 5 doses 4-weekly) in this extension study / Certolizumab pegol (CZP) 400 mg (3 doses 2-weekly) in the 6-week double-blind main study (2014-004399-42)

    Primary: Percentage of Crohn’s Disease Activity Index (CDAI) Responders at Week 34

    		 Close Top of page
    End point title
    		 Percentage of Crohn’s Disease Activity Index (CDAI) Responders at Week 34 [1]
    End point description
    Crohn's disease activity index (CDAI) responders are subjects achieving either clinical response (a reduction in CDAI score of ≥100 points from Week 0), or remission (CDAI ≤150). CDAI is used to quantify the symptoms of subjects with Crohn's disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
    End point type
    Primary
    End point timeframe
    Week 0 and Week 34 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 34' is 26 weeks after the first visit in this extension study.
    Notes
    [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No formal statistical hypothesis testing was planned for this study. Results were summarized in tables as descriptive statistics only.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    12
    7
    7
    Units: Percentage of subjects
    number (not applicable)
        Percentage of CDAI responders
    66.7
    28.6
    42.9
        Percentage of CDAI non-responders
    33.3
    71.4
    57.1
    No statistical analyses for this end point

    Secondary: Change from Week 0 in Crohn's Disease Activity Index (CDAI) Score at Week 8

    		 Close Top of page
    End point title
    		 Change from Week 0 in Crohn's Disease Activity Index (CDAI) Score at Week 8
    End point description
    Crohn's disease activity index (CDAI) is used to quantify the symptoms of subjects with Crohn's disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.
    End point type
    Secondary
    End point timeframe
    Week 0 and Week 8 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 8' is the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    12
    7
    7
    Units: score on a scale
    arithmetic mean (standard deviation)
        mean (standard deviation)
    -20.5 ( 81.6 )
    -53.1 ( 38.1 )
    -63.8 ( 26.4 )
    No statistical analyses for this end point

    Secondary: Change from Week 0 in Crohn's Disease Activity Index (CDAI) Score at Week 10

    		 Close Top of page
    End point title
    		 Change from Week 0 in Crohn's Disease Activity Index (CDAI) Score at Week 10
    End point description
    Crohn's disease activity index (CDAI) is used to quantify the symptoms of subjects with Crohn's disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.
    End point type
    Secondary
    End point timeframe
    Week 0 and Week 10 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 10' is 2 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    12
    7
    7
    Units: score on a scale
    arithmetic mean (standard deviation)
        mean (standard deviation)
    -96.1 ( 76.1 )
    -100.3 ( 35.4 )
    -90 ( 18.2 )
    No statistical analyses for this end point

    Secondary: Change from Week 0 in Crohn's Disease Activity Index (CDAI) Score at Week 12

    		 Close Top of page
    End point title
    		 Change from Week 0 in Crohn's Disease Activity Index (CDAI) Score at Week 12
    End point description
    Crohn's disease activity index (CDAI) is used to quantify the symptoms of subjects with Crohn's disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.
    End point type
    Secondary
    End point timeframe
    Week 0 and Week 12 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 12' is 4 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    12
    7
    7
    Units: score on a scale
    arithmetic mean (standard deviation)
        mean (standard deviation)
    -101.3 ( 56.6 )
    -100.5 ( 49.3 )
    -109.9 ( 36.7 )
    No statistical analyses for this end point

    Secondary: Change from Week 0 in Crohn's Disease Activity Index (CDAI) Score at Week 14

    		 Close Top of page
    End point title
    		 Change from Week 0 in Crohn's Disease Activity Index (CDAI) Score at Week 14
    End point description
    Crohn's disease activity index (CDAI) is used to quantify the symptoms of subjects with Crohn's disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.
    End point type
    Secondary
    End point timeframe
    Week 0 and Week 14 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 14' is 6 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    12
    7
    7
    Units: score on a scale
    arithmetic mean (standard deviation)
        mean (standard deviation)
    -124.3 ( 50.4 )
    -131.7 ( 41.3 )
    -147 ( 45.2 )
    No statistical analyses for this end point

    Secondary: Change from Week 0 in Crohn's Disease Activity Index (CDAI) Score at Week 16

    		 Close Top of page
    End point title
    		 Change from Week 0 in Crohn's Disease Activity Index (CDAI) Score at Week 16
    End point description
    Crohn's disease activity index (CDAI) is used to quantify the symptoms of subjects with Crohn's disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.
    End point type
    Secondary
    End point timeframe
    Week 0 and Week 16 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 16' is 8 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    12
    7
    7
    Units: score on a scale
    arithmetic mean (standard deviation)
        mean (standard deviation)
    -121 ( 57.7 )
    -70.4 ( 84.1 )
    -136.2 ( 32.2 )
    No statistical analyses for this end point

    Secondary: Change from Week 0 in Crohn's Disease Activity Index (CDAI) Score at Week 20

    		 Close Top of page
    End point title
    		 Change from Week 0 in Crohn's Disease Activity Index (CDAI) Score at Week 20
    End point description
    Crohn's disease activity index (CDAI) is used to quantify the symptoms of subjects with Crohn's disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.
    End point type
    Secondary
    End point timeframe
    Week 0 and Week 20 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 20' is 12 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    11
    7
    7
    Units: score on a scale
    arithmetic mean (standard deviation)
        mean (standard deviation)
    -105.3 ( 82.9 )
    -79.6 ( 60.9 )
    -130.9 ( 62.5 )
    No statistical analyses for this end point

    Secondary: Change from Week 0 in Crohn's Disease Activity Index (CDAI) Score at Week 24

    		 Close Top of page
    End point title
    		 Change from Week 0 in Crohn's Disease Activity Index (CDAI) Score at Week 24
    End point description
    Crohn's disease activity index (CDAI) is used to quantify the symptoms of subjects with Crohn's disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.
    End point type
    Secondary
    End point timeframe
    Week 0 and Week 24 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 24' is 16 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    9
    7
    7
    Units: score on a scale
    arithmetic mean (standard deviation)
        mean (standard deviation)
    -89.8 ( 79.8 )
    -70.6 ( 91.3 )
    -150.2 ( 48 )
    No statistical analyses for this end point

    Secondary: Change from Week 0 in Crohn's Disease Activity Index (CDAI) Score at Week 28

    		 Close Top of page
    End point title
    		 Change from Week 0 in Crohn's Disease Activity Index (CDAI) Score at Week 28
    End point description
    Crohn's disease activity index (CDAI) is used to quantify the symptoms of subjects with Crohn's disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.
    End point type
    Secondary
    End point timeframe
    Week 0 and Week 28 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 28' is 20 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    9
    7
    7
    Units: score on a scale
    arithmetic mean (standard deviation)
        mean (standard deviation)
    -118.2 ( 62.6 )
    -67.3 ( 77.1 )
    -154.8 ( 74.2 )
    No statistical analyses for this end point

    Secondary: Change from Week 0 in Crohn's Disease Activity Index (CDAI) Score at Week 32

    		 Close Top of page
    End point title
    		 Change from Week 0 in Crohn's Disease Activity Index (CDAI) Score at Week 32
    End point description
    Crohn's disease activity index (CDAI) is used to quantify the symptoms of subjects with Crohn's disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.
    End point type
    Secondary
    End point timeframe
    Week 0 and Week 32 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 32' is 24 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    8
    5
    6
    Units: score on a scale
    arithmetic mean (standard deviation)
        mean (standard deviation)
    -89 ( 88.3 )
    -77.3 ( 70.9 )
    -128.3 ( 75.3 )
    No statistical analyses for this end point

    Secondary: Change from Week 0 in Crohn's Disease Activity Index (CDAI) Score at Week 34

    		 Close Top of page
    End point title
    		 Change from Week 0 in Crohn's Disease Activity Index (CDAI) Score at Week 34
    End point description
    Crohn's disease activity index (CDAI) is used to quantify the symptoms of subjects with Crohn's disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.
    End point type
    Secondary
    End point timeframe
    Week 0 and Week 34 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 34' is 26 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    8
    5
    5
    Units: score on a scale
    arithmetic mean (standard deviation)
        mean (standard deviation)
    -134.9 ( 39.3 )
    -97.4 ( 33.1 )
    -132.7 ( 89.7 )
    No statistical analyses for this end point

    Secondary: Change from Week 0 in Crohn's Disease Activity Index (CDAI) Score at Last Visit (Week 34 for completers or the Withdrawal Visit for premature withdrawals)

    		 Close Top of page
    End point title
    		 Change from Week 0 in Crohn's Disease Activity Index (CDAI) Score at Last Visit (Week 34 for completers or the Withdrawal Visit for premature withdrawals)
    End point description
    Crohn's disease activity index (CDAI) is used to quantify the symptoms of subjects with Crohn's disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.
    End point type
    Secondary
    End point timeframe
    Week 0 and Last Visit (Week 34 relative to the start of the 6-week double-blind main study (NCT00291668) for completers or the Withdrawal Visit for premature withdrawals). 'Week 34' is 26 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    11
    6
    5
    Units: score on a scale
    arithmetic mean (standard deviation)
        mean (standard deviation)
    -112 ( 75.6 )
    -61 ( 93.7 )
    -132.7 ( 89.7 )
    No statistical analyses for this end point

    Secondary: Percentage of Crohn's Disease Activity Index (CDAI) responders at Week 8

    		 Close Top of page
    End point title
    		 Percentage of Crohn's Disease Activity Index (CDAI) responders at Week 8
    End point description
    Crohn's disease activity index (CDAI) responders are subjects achieving either clinical response (a reduction in CDAI score of ≥100 points from Week 0), or remission (CDAI ≤150). CDAI is used to quantify the symptoms of subjects with Crohn's disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
    End point type
    Secondary
    End point timeframe
    Week 0 and Week 8 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 8' is the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    12
    7
    7
    Units: Percentage of subjects
    number (not applicable)
        Percentage of CDAI responders
    8.3
    14.3
    14.3
        Percentage of CDAI non-responders
    91.7
    85.7
    85.7
    No statistical analyses for this end point

    Secondary: Percentage of Crohn's Disease Activity Index (CDAI) responders at Week 10

    		 Close Top of page
    End point title
    		 Percentage of Crohn's Disease Activity Index (CDAI) responders at Week 10
    End point description
    Crohn's disease activity index (CDAI) responders are subjects achieving either clinical response (a reduction in CDAI score of ≥100 points from Week 0), or remission (CDAI ≤150). CDAI is used to quantify the symptoms of subjects with Crohn's disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
    End point type
    Secondary
    End point timeframe
    Week 0 and Week 10 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 10' is 2 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    12
    7
    7
    Units: Percentage of subjects
    number (not applicable)
        Percentage of CDAI responders
    41.7
    71.4
    42.9
        Percentage of CDAI non-responders
    58.3
    28.6
    57.1
    No statistical analyses for this end point

    Secondary: Percentage of Crohn's Disease Activity Index (CDAI) responders at Week 12

    		 Close Top of page
    End point title
    		 Percentage of Crohn's Disease Activity Index (CDAI) responders at Week 12
    End point description
    Crohn's disease activity index (CDAI) responders are subjects achieving either clinical response (a reduction in CDAI score of ≥100 points from Week 0), or remission (CDAI ≤150). CDAI is used to quantify the symptoms of subjects with Crohn's disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
    End point type
    Secondary
    End point timeframe
    Week 0 and Week 12 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 12' is 4 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    12
    7
    7
    Units: Percentage of subjects
    number (not applicable)
        Percentage of CDAI responders
    50
    71.4
    57.1
        Percentage of CDAI non-responders
    50
    28.6
    42.9
    No statistical analyses for this end point

    Secondary: Percentage of Crohn's Disease Activity Index (CDAI) responders at Week 14

    		 Close Top of page
    End point title
    		 Percentage of Crohn's Disease Activity Index (CDAI) responders at Week 14
    End point description
    Crohn's disease activity index (CDAI) responders are subjects achieving either clinical response (a reduction in CDAI score of ≥100 points from Week 0), or remission (CDAI ≤150). CDAI is used to quantify the symptoms of subjects with Crohn's disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
    End point type
    Secondary
    End point timeframe
    Week 0 and Week 14 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 14' is 6 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    12
    7
    7
    Units: Percentage of subjects
    number (not applicable)
        Percentage of CDAI responders
    100
    100
    100
        Percentage of CDAI non-responders
    0
    0
    0
    No statistical analyses for this end point

    Secondary: Percentage of Crohn's Disease Activity Index (CDAI) responders at Week 16

    		 Close Top of page
    End point title
    		 Percentage of Crohn's Disease Activity Index (CDAI) responders at Week 16
    End point description
    Crohn's disease activity index (CDAI) responders are subjects achieving either clinical response (a reduction in CDAI score of ≥100 points from Week 0), or remission (CDAI ≤150). CDAI is used to quantify the symptoms of subjects with Crohn's disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
    End point type
    Secondary
    End point timeframe
    Week 0 and Week 16 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 16' is 8 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    12
    7
    7
    Units: Percentage of subjects
    number (not applicable)
        Percentage of CDAI responders
    66.7
    42.9
    85.7
        Percentage of CDAI non-responders
    33.3
    57.1
    14.3
    No statistical analyses for this end point

    Secondary: Percentage of Crohn's Disease Activity Index (CDAI) responders at Week 20

    		 Close Top of page
    End point title
    		 Percentage of Crohn's Disease Activity Index (CDAI) responders at Week 20
    End point description
    Crohn's disease activity index (CDAI) responders are subjects achieving either clinical response (a reduction in CDAI score of ≥100 points from Week 0), or remission (CDAI ≤150). CDAI is used to quantify the symptoms of subjects with Crohn's disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
    End point type
    Secondary
    End point timeframe
    Week 0 and Week 20 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 20' is 12 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    12
    7
    7
    Units: Percentage of subjects
    number (not applicable)
        Percentage of CDAI responders
    41.7
    28.6
    85.7
        Percentage of CDAI non-responders
    58.3
    71.4
    14.3
    No statistical analyses for this end point

    Secondary: Percentage of Crohn's Disease Activity Index (CDAI) responders at Week 24

    		 Close Top of page
    End point title
    		 Percentage of Crohn's Disease Activity Index (CDAI) responders at Week 24
    End point description
    Crohn's disease activity index (CDAI) responders are subjects achieving either clinical response (a reduction in CDAI score of ≥100 points from Week 0), or remission (CDAI ≤150). CDAI is used to quantify the symptoms of subjects with Crohn's disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
    End point type
    Secondary
    End point timeframe
    Week 0 and Week 24 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 24' is 16 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    12
    7
    7
    Units: Percentage of subjects
    number (not applicable)
        Percentage of CDAI responders
    41.7
    57.1
    71.4
        Percentage of CDAI non-responders
    58.3
    42.9
    28.6
    No statistical analyses for this end point

    Secondary: Percentage of Crohn's Disease Activity Index (CDAI) responders at Week 28

    		 Close Top of page
    End point title
    		 Percentage of Crohn's Disease Activity Index (CDAI) responders at Week 28
    End point description
    Crohn's disease activity index (CDAI) responders are subjects achieving either clinical response (a reduction in CDAI score of ≥100 points from Week 0), or remission (CDAI ≤150). CDAI is used to quantify the symptoms of subjects with Crohn's disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
    End point type
    Secondary
    End point timeframe
    Week 0 and Week 28 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 28' is 20 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    12
    7
    7
    Units: Percentage of subjects
    number (not applicable)
        Percentage of CDAI responders
    50
    28.6
    57.1
        Percentage of CDAI non-responders
    50
    71.4
    42.9
    No statistical analyses for this end point

    Secondary: Percentage of Crohn's Disease Activity Index (CDAI) responders at Week 32

    		 Close Top of page
    End point title
    		 Percentage of Crohn's Disease Activity Index (CDAI) responders at Week 32
    End point description
    Crohn's disease activity index (CDAI) responders are subjects achieving either clinical response (a reduction in CDAI score of ≥100 points from Week 0), or remission (CDAI ≤150). CDAI is used to quantify the symptoms of subjects with Crohn's disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
    End point type
    Secondary
    End point timeframe
    Week 0 and Week 32 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 32' is 24 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    12
    7
    7
    Units: Percentage of subjects
    number (not applicable)
        Percentage of CDAI responders
    33.3
    28.6
    57.1
        Percentage of CDAI non-responders
    66.7
    71.4
    42.9
    No statistical analyses for this end point

    Secondary: Percentage of Crohn's Disease Activity Index (CDAI) responders at Last Visit (Week 34 for completers or the Withdrawal Visit for premature withdrawals)

    		 Close Top of page
    End point title
    		 Percentage of Crohn's Disease Activity Index (CDAI) responders at Last Visit (Week 34 for completers or the Withdrawal Visit for premature withdrawals)
    End point description
    Crohn's disease activity index (CDAI) responders are subjects achieving either clinical response (a reduction in CDAI score of ≥100 points from Week 0), or remission (CDAI ≤150). CDAI is used to quantify the symptoms of subjects with Crohn's disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
    End point type
    Secondary
    End point timeframe
    Week 0 and Last Visit (Week 34 relative to the start of the 6-week double-blind main study (NCT00291668) for completers or the Withdrawal Visit for premature withdrawals). 'Week 34' is 26 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    12
    7
    7
    Units: Percentage of subjects
    number (not applicable)
        Percentage of CDAI responders
    66.7
    28.6
    42.9
        Percentage of CDAI non-responders
    33.3
    71.4
    57.1
    No statistical analyses for this end point

    Secondary: Percentage of subjects achieving remission at Week 8

    		 Close Top of page
    End point title
    		 Percentage of subjects achieving remission at Week 8
    End point description
    Crohn's disease activity index (CDAI) is used to quantify the symptoms of subjects with Crohn's disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
    End point type
    Secondary
    End point timeframe
    Week 8 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 8' is the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    12
    7
    7
    Units: Percentage of subjects
    number (not applicable)
        Percentage of subjects in remission
    0
    0
    14.3
        Percentage of subjects not in remission
    100
    100
    85.7
    No statistical analyses for this end point

    Secondary: Percentage of subjects achieving remission at Week 10

    		 Close Top of page
    End point title
    		 Percentage of subjects achieving remission at Week 10
    End point description
    Crohn's disease activity index (CDAI) is used to quantify the symptoms of subjects with Crohn's disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
    End point type
    Secondary
    End point timeframe
    Week 10 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 10' is 2 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    12
    7
    7
    Units: Percentage of subjects
    number (not applicable)
        Percentage of subjects in remission
    33.3
    42.9
    14.3
        Percentage of subjects not in remission
    66.7
    57.1
    85.7
    No statistical analyses for this end point

    Secondary: Percentage of subjects achieving remission at Week 12

    		 Close Top of page
    End point title
    		 Percentage of subjects achieving remission at Week 12
    End point description
    Crohn's disease activity index (CDAI) is used to quantify the symptoms of subjects with Crohn's disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
    End point type
    Secondary
    End point timeframe
    Week 12 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 12' is 4 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    12
    7
    7
    Units: Percentage of subjects
    number (not applicable)
        Percentage of subjects in remission
    25
    42.9
    42.9
        Percentage of subjects not in remission
    75
    57.1
    57.1
    No statistical analyses for this end point

    Secondary: Percentage of subjects achieving remission at Week 14

    		 Close Top of page
    End point title
    		 Percentage of subjects achieving remission at Week 14
    End point description
    Crohn's disease activity index (CDAI) is used to quantify the symptoms of subjects with Crohn's disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
    End point type
    Secondary
    End point timeframe
    Week 14 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 14' is 6 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    12
    7
    7
    Units: Percentage of subjects
    number (not applicable)
        Percentage of subjects in remission
    66.7
    71.4
    71.4
        Percentage of subjects not in remission
    33.3
    28.6
    28.6
    No statistical analyses for this end point

    Secondary: Percentage of subjects achieving remission at Week 16

    		 Close Top of page
    End point title
    		 Percentage of subjects achieving remission at Week 16
    End point description
    Crohn's disease activity index (CDAI) is used to quantify the symptoms of subjects with Crohn's disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
    End point type
    Secondary
    End point timeframe
    Week 16 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 16' is 8 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    12
    7
    7
    Units: Percentage of subjects
    number (not applicable)
        Percentage of subjects in remission
    33.3
    28.6
    57.1
        Percentage of subjects not in remission
    66.7
    71.4
    42.9
    No statistical analyses for this end point

    Secondary: Percentage of subjects achieving remission at Week 20

    		 Close Top of page
    End point title
    		 Percentage of subjects achieving remission at Week 20
    End point description
    Crohn's disease activity index (CDAI) is used to quantify the symptoms of subjects with Crohn's disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
    End point type
    Secondary
    End point timeframe
    Week 20 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 20' is 12 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    12
    7
    7
    Units: Percentage of subjects
    number (not applicable)
        Percentage of subjects in remission
    33.3
    28.6
    57.1
        Percentage of subjects not in remission
    66.7
    71.4
    42.9
    No statistical analyses for this end point

    Secondary: Percentage of subjects achieving remission at Week 24

    		 Close Top of page
    End point title
    		 Percentage of subjects achieving remission at Week 24
    End point description
    Crohn's disease activity index (CDAI) is used to quantify the symptoms of subjects with Crohn's disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
    End point type
    Secondary
    End point timeframe
    Week 24 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 24' is 16 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    12
    7
    7
    Units: Percentage of subjects
    number (not applicable)
        Percentage of subjects in remission
    16.7
    42.9
    71.4
        Percentage of subjects not in remission
    83.3
    57.1
    28.6
    No statistical analyses for this end point

    Secondary: Percentage of subjects achieving remission at Week 28

    		 Close Top of page
    End point title
    		 Percentage of subjects achieving remission at Week 28
    End point description
    Crohn's disease activity index (CDAI) is used to quantify the symptoms of subjects with Crohn's disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
    End point type
    Secondary
    End point timeframe
    Week 28 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 28' is 20 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    12
    7
    7
    Units: Percentage of subjects
    number (not applicable)
        Percentage of subjects in remission
    25
    28.6
    57.1
        Percentage of subjects not in remission
    75
    71.4
    42.9
    No statistical analyses for this end point

    Secondary: Percentage of subjects achieving remission at Week 32

    		 Close Top of page
    End point title
    		 Percentage of subjects achieving remission at Week 32
    End point description
    Crohn's disease activity index (CDAI) is used to quantify the symptoms of subjects with Crohn's disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
    End point type
    Secondary
    End point timeframe
    Week 32 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 32' is 24 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    12
    7
    7
    Units: Percentage of subjects
    number (not applicable)
        Percentage of subjects in remission
    16.7
    28.6
    42.9
        Percentage of subjects not in remission
    83.3
    71.4
    57.1
    No statistical analyses for this end point

    Secondary: Percentage of subjects achieving remission at Week 34

    		 Close Top of page
    End point title
    		 Percentage of subjects achieving remission at Week 34
    End point description
    Crohn's disease activity index (CDAI) is used to quantify the symptoms of subjects with Crohn's disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
    End point type
    Secondary
    End point timeframe
    Week 34 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 34' is 26 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    12
    7
    7
    Units: Percentage of subjects
    number (not applicable)
        Percentage of subjects in remission
    33.3
    28.6
    42.9
        Percentage of subjects not in remission
    66.7
    71.4
    57.1
    No statistical analyses for this end point

    Secondary: Percentage of subjects achieving remission at Last Visit (Week 34 for completers or the Withdrawal Visit for premature withdrawals)

    		 Close Top of page
    End point title
    		 Percentage of subjects achieving remission at Last Visit (Week 34 for completers or the Withdrawal Visit for premature withdrawals)
    End point description
    Crohn's disease activity index (CDAI) is used to quantify the symptoms of subjects with Crohn's disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
    End point type
    Secondary
    End point timeframe
    Last Visit (Week 34 relative to the start of the 6-week double-blind main study (NCT00291668) for completers or the Withdrawal Visit for premature withdrawals). 'Week 34' is 26 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    12
    7
    7
    Units: Percentage of subjects
    number (not applicable)
        Percentage of subjects in remission
    33.3
    28.6
    42.9
        Percentage of subjects not in remission
    66.7
    71.4
    57.1
    No statistical analyses for this end point

    Secondary: Time to disease progression

    		 Close Top of page
    End point title
    		 Time to disease progression
    End point description
    Time to disease progression is defined as the earliest of: - time to an increase from Week 14 of ≥100 points in Crohn’s Disease Activity Index (CDAI) score and CDAI>175 points for at least 2 consecutive visits, - time to use of rescue therapy, or, - time to subject withdrawal from the study.
    End point type
    Secondary
    End point timeframe
    Week 14 to Week 34 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 14' is the visit at which response to re-induction is assessed and 'Week 34' is 26 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    0 [2]
    0 [3]
    0 [4]
    Units: days
    median (confidence interval 95%)
        median (95% CI)
    ( to )
    ( to )
    ( to )
    Notes
    [2] - No data displayed because Outcome Measure has zero total participants analyzed.
    [3] - No data displayed because Outcome Measure has zero total participants analyzed.
    [4] - No data displayed because Outcome Measure has zero total participants analyzed.
    No statistical analyses for this end point

    Secondary: Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Global Score at Week 8

    		 Close Top of page
    End point title
    		 Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Global Score at Week 8
    End point description
    The IBDQ Global Score is the sum of 32 responses, each ranging from 0 to 7, thus the Global Score ranges from 0 to 224; a higher score indicating a better quality of life.
    End point type
    Secondary
    End point timeframe
    Week 0 and Week 8 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 8' is the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    12
    7
    7
    Units: score on a scale
    arithmetic mean (standard deviation)
        mean (standard deviation)
    4.6 ( 15.3 )
    9.1 ( 7.5 )
    5.3 ( 13.8 )
    No statistical analyses for this end point

    Secondary: Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Global Score at Week 10

    		 Close Top of page
    End point title
    		 Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Global Score at Week 10
    End point description
    The IBDQ Global Score is the sum of 32 responses, each ranging from 0 to 7, thus the Global Score ranges from 0 to 224; a higher score indicating a better quality of life.
    End point type
    Secondary
    End point timeframe
    Week 0 and Week 10 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 10' is 2 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    12
    7
    7
    Units: score on a scale
    arithmetic mean (standard deviation)
        mean (standard deviation)
    17 ( 17.5 )
    20.9 ( 24.9 )
    15.1 ( 13.4 )
    No statistical analyses for this end point

    Secondary: Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Global Score at Week 12

    		 Close Top of page
    End point title
    		 Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Global Score at Week 12
    End point description
    The IBDQ Global Score is the sum of 32 responses, each ranging from 0 to 7, thus the Global Score ranges from 0 to 224; a higher score indicating a better quality of life.
    End point type
    Secondary
    End point timeframe
    Week 0 and Week 12 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 12' is 4 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    12
    7
    7
    Units: score on a scale
    arithmetic mean (standard deviation)
        mean (standard deviation)
    17.3 ( 12 )
    26.3 ( 33.6 )
    20.1 ( 16.6 )
    No statistical analyses for this end point

    Secondary: Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Global Score at Week 14

    		 Close Top of page
    End point title
    		 Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Global Score at Week 14
    End point description
    The IBDQ Global Score is the sum of 32 responses, each ranging from 0 to 7, thus the Global Score ranges from 0 to 224; a higher score indicating a better quality of life.
    End point type
    Secondary
    End point timeframe
    Week 0 and Week 14 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 14' is 6 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    12
    7
    7
    Units: score on a scale
    arithmetic mean (standard deviation)
        mean (standard deviation)
    20.1 ( 12.3 )
    28.6 ( 22.9 )
    26.3 ( 16.1 )
    No statistical analyses for this end point

    Secondary: Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Global Score at Week 16

    		 Close Top of page
    End point title
    		 Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Global Score at Week 16
    End point description
    The IBDQ Global Score is the sum of 32 responses, each ranging from 0 to 7, thus the Global Score ranges from 0 to 224; a higher score indicating a better quality of life.
    End point type
    Secondary
    End point timeframe
    Week 0 and Week 16 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 16' is 8 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    12
    7
    7
    Units: score on a scale
    arithmetic mean (standard deviation)
        mean (standard deviation)
    16.3 ( 12.2 )
    15.3 ( 19.1 )
    20 ( 16.4 )
    No statistical analyses for this end point

    Secondary: Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Global Score at Week 20

    		 Close Top of page
    End point title
    		 Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Global Score at Week 20
    End point description
    The IBDQ Global Score is the sum of 32 responses, each ranging from 0 to 7, thus the Global Score ranges from 0 to 224; a higher score indicating a better quality of life.
    End point type
    Secondary
    End point timeframe
    Week 0 and Week 20 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 20' is 12 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    11
    7
    7
    Units: score on a scale
    arithmetic mean (standard deviation)
        mean (standard deviation)
    12.2 ( 16 )
    18.4 ( 27.5 )
    15.9 ( 14.7 )
    No statistical analyses for this end point

    Secondary: Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Global Score at Week 24

    		 Close Top of page
    End point title
    		 Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Global Score at Week 24
    End point description
    The IBDQ Global Score is the sum of 32 responses, each ranging from 0 to 7, thus the Global Score ranges from 0 to 224; a higher score indicating a better quality of life.
    End point type
    Secondary
    End point timeframe
    Week 0 and Week 24 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 24' is 16 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    9
    7
    7
    Units: score on a scale
    arithmetic mean (standard deviation)
        mean (standard deviation)
    8.3 ( 14.5 )
    7.6 ( 23.3 )
    18.4 ( 18 )
    No statistical analyses for this end point

    Secondary: Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Global Score at Week 28

    		 Close Top of page
    End point title
    		 Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Global Score at Week 28
    End point description
    The IBDQ Global Score is the sum of 32 responses, each ranging from 0 to 7, thus the Global Score ranges from 0 to 224; a higher score indicating a better quality of life.
    End point type
    Secondary
    End point timeframe
    Week 0 and Week 28 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 28' is 20 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    9
    7
    7
    Units: score on a scale
    arithmetic mean (standard deviation)
        mean (standard deviation)
    14.9 ( 20 )
    11.4 ( 24.3 )
    15.9 ( 19.3 )
    No statistical analyses for this end point

    Secondary: Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Global Score at Week 32

    		 Close Top of page
    End point title
    		 Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Global Score at Week 32
    End point description
    The IBDQ Global Score is the sum of 32 responses, each ranging from 0 to 7, thus the Global Score ranges from 0 to 224; a higher score indicating a better quality of life.
    End point type
    Secondary
    End point timeframe
    Week 0 and Week 32 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 32' is 24 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    8
    5
    6
    Units: score on a scale
    arithmetic mean (standard deviation)
        mean (standard deviation)
    11.3 ( 17.8 )
    11.2 ( 21.7 )
    25.3 ( 17 )
    No statistical analyses for this end point

    Secondary: Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Global Score at Week 34

    		 Close Top of page
    End point title
    		 Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Global Score at Week 34
    End point description
    The IBDQ Global Score is the sum of 32 responses, each ranging from 0 to 7, thus the Global Score ranges from 0 to 224; a higher score indicating a better quality of life.
    End point type
    Secondary
    End point timeframe
    Week 0 and Week 34 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 34' is 26 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    8
    5
    5
    Units: score on a scale
    arithmetic mean (standard deviation)
        mean (standard deviation)
    21.6 ( 16.9 )
    14.8 ( 23.6 )
    20.6 ( 17.6 )
    No statistical analyses for this end point

    Secondary: Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Global Score at Last Visit (Week 34 for completers or the Withdrawal Visit for premature withdrawals)

    		 Close Top of page
    End point title
    		 Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Global Score at Last Visit (Week 34 for completers or the Withdrawal Visit for premature withdrawals)
    End point description
    The Inflammatory Bowel Disease Questionnaire (IBDQ) Global Score is the sum of 32 responses, each ranging from 0 to 7, thus the Global Score ranges from 0 to 224; a higher score indicating a better quality of life.
    End point type
    Secondary
    End point timeframe
    Week 0 and Last Visit (Week 34 relative to the start of the 6-week double-blind main study (NCT00291668) for completers or the Withdrawal Visit for premature withdrawals). 'Week 34' is 26 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    11
    6
    5
    Units: score on a scale
    arithmetic mean (standard deviation)
        mean (standard deviation)
    15.6 ( 19.5 )
    10.8 ( 23.3 )
    20.6 ( 17.6 )
    No statistical analyses for this end point

    Secondary: Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Bowel Domain Sub-Score at Week 8

    		 Close Top of page
    End point title
    		 Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Bowel Domain Sub-Score at Week 8
    End point description
    The IBDQ Bowel Domain Sub-Score is the sum of 8 responses, each ranging from 0 to 7, thus the Sub-Score ranges from 0 to 56; a higher score indicating a better quality of life.
    End point type
    Secondary
    End point timeframe
    Week 0 and Week 8 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 8' is the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    12
    7
    7
    Units: score on a scale
    arithmetic mean (standard deviation)
        mean (standard deviation)
    1.9 ( 7.5 )
    6.4 ( 5.6 )
    2.4 ( 5.3 )
    No statistical analyses for this end point

    Secondary: Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Bowel Domain Sub-Score at Week 10

    		 Close Top of page
    End point title
    		 Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Bowel Domain Sub-Score at Week 10
    End point description
    The IBDQ Bowel Domain Sub-Score is the sum of 8 responses, each ranging from 0 to 7, thus the Sub-Score ranges from 0 to 56; a higher score indicating a better quality of life.
    End point type
    Secondary
    End point timeframe
    Week 0 and Week 10 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 10' is 2 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    12
    7
    7
    Units: score on a scale
    arithmetic mean (standard deviation)
        mean (standard deviation)
    6.2 ( 8.4 )
    10.6 ( 8.4 )
    5.9 ( 7.1 )
    No statistical analyses for this end point

    Secondary: Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Bowel Domain Sub-Score at Week 12

    		 Close Top of page
    End point title
    		 Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Bowel Domain Sub-Score at Week 12
    End point description
    The IBDQ Bowel Domain Sub-Score is the sum of 8 responses, each ranging from 0 to 7, thus the Sub-Score ranges from 0 to 56; a higher score indicating a better quality of life.
    End point type
    Secondary
    End point timeframe
    Week 0 and Week 12 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 12' is 4 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    12
    7
    7
    Units: score on a scale
    arithmetic mean (standard deviation)
        mean (standard deviation)
    5.7 ( 4.4 )
    11.7 ( 9.7 )
    7.4 ( 7.9 )
    No statistical analyses for this end point

    Secondary: Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Bowel Domain Sub-Score at Week 14

    		 Close Top of page
    End point title
    		 Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Bowel Domain Sub-Score at Week 14
    End point description
    The IBDQ Bowel Domain Sub-Score is the sum of 8 responses, each ranging from 0 to 7, thus the Sub-Score ranges from 0 to 56; a higher score indicating a better quality of life.
    End point type
    Secondary
    End point timeframe
    Week 0 and Week 14 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 14' is 6 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    12
    7
    7
    Units: score on a scale
    arithmetic mean (standard deviation)
        mean (standard deviation)
    6.9 ( 5.6 )
    12.3 ( 9.3 )
    9.3 ( 7 )
    No statistical analyses for this end point

    Secondary: Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Bowel Domain Sub-Score at Week 16

    		 Close Top of page
    End point title
    		 Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Bowel Domain Sub-Score at Week 16
    End point description
    The IBDQ Bowel Domain Sub-Score is the sum of 8 responses, each ranging from 0 to 7, thus the Sub-Score ranges from 0 to 56; a higher score indicating a better quality of life.
    End point type
    Secondary
    End point timeframe
    Week 0 and Week 16 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 16' is 8 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    12
    7
    7
    Units: score on a scale
    arithmetic mean (standard deviation)
        mean (standard deviation)
    5.2 ( 6.3 )
    8.4 ( 9.9 )
    6.3 ( 7.2 )
    No statistical analyses for this end point

    Secondary: Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Bowel Domain Sub-Score at Week 20

    		 Close Top of page
    End point title
    		 Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Bowel Domain Sub-Score at Week 20
    End point description
    The IBDQ Bowel Domain Sub-Score is the sum of 8 responses, each ranging from 0 to 7, thus the Sub-Score ranges from 0 to 56; a higher score indicating a better quality of life.
    End point type
    Secondary
    End point timeframe
    Week 0 and Week 20 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 20' is 12 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    11
    7
    7
    Units: score on a scale
    arithmetic mean (standard deviation)
        mean (standard deviation)
    3.5 ( 7.4 )
    9.9 ( 11.7 )
    5.1 ( 5.5 )
    No statistical analyses for this end point

    Secondary: Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Bowel Domain Sub-Score at Week 24

    		 Close Top of page
    End point title
    		 Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Bowel Domain Sub-Score at Week 24
    End point description
    The IBDQ Bowel Domain Sub-Score is the sum of 8 responses, each ranging from 0 to 7, thus the Sub-Score ranges from 0 to 56; a higher score indicating a better quality of life.
    End point type
    Secondary
    End point timeframe
    Week 0 and Week 24 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 24' is 16 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    9
    7
    7
    Units: score on a scale
    arithmetic mean (standard deviation)
        mean (standard deviation)
    0.7 ( 5.3 )
    4.7 ( 11 )
    5.6 ( 8.2 )
    No statistical analyses for this end point

    Secondary: Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Bowel Domain Sub-Score at Week 28

    		 Close Top of page
    End point title
    		 Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Bowel Domain Sub-Score at Week 28
    End point description
    The IBDQ Bowel Domain Sub-Score is the sum of 8 responses, each ranging from 0 to 7, thus the Sub-Score ranges from 0 to 56; a higher score indicating a better quality of life.
    End point type
    Secondary
    End point timeframe
    Week 0 and Week 28 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 28' is 20 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    9
    7
    7
    Units: score on a scale
    arithmetic mean (standard deviation)
        mean (standard deviation)
    4.6 ( 6 )
    8.3 ( 10 )
    5.4 ( 8.4 )
    No statistical analyses for this end point

    Secondary: Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Bowel Domain Sub-Score at Week 32

    		 Close Top of page
    End point title
    		 Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Bowel Domain Sub-Score at Week 32
    End point description
    The IBDQ Bowel Domain Sub-Score is the sum of 8 responses, each ranging from 0 to 7, thus the Sub-Score ranges from 0 to 56; a higher score indicating a better quality of life.
    End point type
    Secondary
    End point timeframe
    Week 0 and Week 32 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 32' is 24 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    8
    5
    6
    Units: score on a scale
    arithmetic mean (standard deviation)
        mean (standard deviation)
    3.1 ( 6.7 )
    9.6 ( 11 )
    7.5 ( 5.1 )
    No statistical analyses for this end point

    Secondary: Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Bowel Domain Sub-Score at Week 34

    		 Close Top of page
    End point title
    		 Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Bowel Domain Sub-Score at Week 34
    End point description
    The IBDQ Bowel Domain Sub-Score is the sum of 8 responses, each ranging from 0 to 7, thus the Sub-Score ranges from 0 to 56; a higher score indicating a better quality of life.
    End point type
    Secondary
    End point timeframe
    Week 0 and Week 34 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 34' is 26 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    8
    5
    5
    Units: score on a scale
    arithmetic mean (standard deviation)
        mean (standard deviation)
    7.1 ( 4.9 )
    11.8 ( 9.8 )
    5.8 ( 6.5 )
    No statistical analyses for this end point

    Secondary: Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Bowel Domain Sub-Score at Last Visit (Week 34 for completers or the Withdrawal Visit for premature withdrawals)

    		 Close Top of page
    End point title
    		 Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Bowel Domain Sub-Score at Last Visit (Week 34 for completers or the Withdrawal Visit for premature withdrawals)
    End point description
    The Inflammatory Bowel Disease Questionnaire (IBDQ) Bowel Domain Sub-Score is the sum of 8 responses, each ranging from 0 to 7, thus the Sub-Score ranges from 0 to 56; a higher score indicating a better quality of life.
    End point type
    Secondary
    End point timeframe
    Week 0 and Last Visit (Week 34 relative to the start of the 6-week double-blind main study (NCT00291668) for completers or the Withdrawal Visit for premature withdrawals). 'Week 34' is 26 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    11
    6
    5
    Units: score on a scale
    arithmetic mean (standard deviation)
        mean (standard deviation)
    5.5 ( 6.9 )
    8.3 ( 12.2 )
    5.8 ( 6.5 )
    No statistical analyses for this end point

    Secondary: Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Systemic Domain Sub-Score at Week 8

    		 Close Top of page
    End point title
    		 Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Systemic Domain Sub-Score at Week 8
    End point description
    The IBDQ Systemic Domain Sub-Score is the sum of 8 responses, each ranging from 0 to 7, thus the Sub-Score ranges from 0 to 56; a higher score indicating a better quality of life.
    End point type
    Secondary
    End point timeframe
    Week 0 and Week 8 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 8' is the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    12
    7
    7
    Units: score on a scale
    arithmetic mean (standard deviation)
        mean (standard deviation)
    1.4 ( 3.4 )
    0.6 ( 1.7 )
    1.7 ( 1.6 )
    No statistical analyses for this end point

    Secondary: Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Systemic Domain Sub-Score at Week 10

    		 Close Top of page
    End point title
    		 Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Systemic Domain Sub-Score at Week 10
    End point description
    The IBDQ Systemic Domain Sub-Score is the sum of 8 responses, each ranging from 0 to 7, thus the Sub-Score ranges from 0 to 56; a higher score indicating a better quality of life.
    End point type
    Secondary
    End point timeframe
    Week 0 and Week 10 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 10' is 2 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    12
    7
    7
    Units: score on a scale
    arithmetic mean (standard deviation)
        mean (standard deviation)
    4.6 ( 4.4 )
    3.7 ( 6.2 )
    3.9 ( 1.3 )
    No statistical analyses for this end point

    Secondary: Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Systemic Domain Sub-Score at Week 12

    		 Close Top of page
    End point title
    		 Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Systemic Domain Sub-Score at Week 12
    End point description
    The IBDQ Systemic Domain Sub-Score is the sum of 8 responses, each ranging from 0 to 7, thus the Sub-Score ranges from 0 to 56; a higher score indicating a better quality of life.
    End point type
    Secondary
    End point timeframe
    Week 0 and Week 12 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 12' is 4 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    12
    7
    7
    Units: score on a scale
    arithmetic mean (standard deviation)
        mean (standard deviation)
    5.7 ( 3.2 )
    5 ( 7.3 )
    5.1 ( 2.1 )
    No statistical analyses for this end point

    Secondary: Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Systemic Domain Sub-Score at Week 14

    		 Close Top of page
    End point title
    		 Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Systemic Domain Sub-Score at Week 14
    End point description
    The IBDQ Systemic Domain Sub-Score is the sum of 8 responses, each ranging from 0 to 7, thus the Sub-Score ranges from 0 to 56; a higher score indicating a better quality of life.
    End point type
    Secondary
    End point timeframe
    Week 0 and Week 14 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 14' is 6 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    12
    7
    7
    Units: score on a scale
    arithmetic mean (standard deviation)
        mean (standard deviation)
    5.9 ( 3 )
    6.4 ( 4.3 )
    6.3 ( 3.1 )
    No statistical analyses for this end point

    Secondary: Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Systemic Domain Sub-Score at Week 16

    		 Close Top of page
    End point title
    		 Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Systemic Domain Sub-Score at Week 16
    End point description
    The IBDQ Systemic Domain Sub-Score is the sum of 8 responses, each ranging from 0 to 7, thus the Sub-Score ranges from 0 to 56; a higher score indicating a better quality of life.
    End point type
    Secondary
    End point timeframe
    Week 0 and Week 16 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 16' is 8 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    12
    7
    7
    Units: score on a scale
    arithmetic mean (standard deviation)
        mean (standard deviation)
    5.5 ( 2.4 )
    3.9 ( 3.7 )
    5.3 ( 3.5 )
    No statistical analyses for this end point

    Secondary: Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Systemic Domain Sub-Score at Week 20

    		 Close Top of page
    End point title
    		 Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Systemic Domain Sub-Score at Week 20
    End point description
    The IBDQ Systemic Domain Sub-Score is the sum of 8 responses, each ranging from 0 to 7, thus the Sub-Score ranges from 0 to 56; a higher score indicating a better quality of life.
    End point type
    Secondary
    End point timeframe
    Week 0 and Week 20 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 20' is 12 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    11
    7
    7
    Units: score on a scale
    arithmetic mean (standard deviation)
        mean (standard deviation)
    3.6 ( 4 )
    3.6 ( 6.3 )
    3.6 ( 2.6 )
    No statistical analyses for this end point

    Secondary: Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Systemic Domain Sub-Score at Week 24

    		 Close Top of page
    End point title
    		 Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Systemic Domain Sub-Score at Week 24
    End point description
    The IBDQ Systemic Domain Sub-Score is the sum of 8 responses, each ranging from 0 to 7, thus the Sub-Score ranges from 0 to 56; a higher score indicating a better quality of life.
    End point type
    Secondary
    End point timeframe
    Week 0 and Week 24 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 24' is 16 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    9
    7
    7
    Units: score on a scale
    arithmetic mean (standard deviation)
        mean (standard deviation)
    3.1 ( 2.9 )
    2.1 ( 5.9 )
    4.1 ( 2.7 )
    No statistical analyses for this end point

    Secondary: Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Systemic Domain Sub-Score at Week 28

    		 Close Top of page
    End point title
    		 Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Systemic Domain Sub-Score at Week 28
    End point description
    The IBDQ Systemic Domain Sub-Score is the sum of 8 responses, each ranging from 0 to 7, thus the Sub-Score ranges from 0 to 56; a higher score indicating a better quality of life.
    End point type
    Secondary
    End point timeframe
    Week 0 and Week 28 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 28' is 20 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    9
    7
    7
    Units: score on a scale
    arithmetic mean (standard deviation)
        mean (standard deviation)
    3 ( 6.1 )
    3 ( 5.8 )
    4.4 ( 3.6 )
    No statistical analyses for this end point

    Secondary: Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Systemic Domain Sub-Score at Week 32

    		 Close Top of page
    End point title
    		 Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Systemic Domain Sub-Score at Week 32
    End point description
    The IBDQ Systemic Domain Sub-Score is the sum of 8 responses, each ranging from 0 to 7, thus the Sub-Score ranges from 0 to 56; a higher score indicating a better quality of life.
    End point type
    Secondary
    End point timeframe
    Week 0 and Week 32 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 32' is 24 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    8
    5
    6
    Units: score on a scale
    arithmetic mean (standard deviation)
        mean (standard deviation)
    3.4 ( 4.3 )
    0.4 ( 3.1 )
    6.8 ( 3.8 )
    No statistical analyses for this end point

    Secondary: Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Systemic Domain Sub-Score at Week 34

    		 Close Top of page
    End point title
    		 Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Systemic Domain Sub-Score at Week 34
    End point description
    The IBDQ Systemic Domain Sub-Score is the sum of 8 responses, each ranging from 0 to 7, thus the Sub-Score ranges from 0 to 56; a higher score indicating a better quality of life.
    End point type
    Secondary
    End point timeframe
    Week 0 and Week 34 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 34' is 26 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    8
    5
    5
    Units: score on a scale
    arithmetic mean (standard deviation)
        mean (standard deviation)
    5 ( 3.2 )
    3 ( 4.8 )
    5.4 ( 2.1 )
    No statistical analyses for this end point

    Secondary: Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Systemic Domain Sub-Score at Last Visit (Week 34 for completers or the Withdrawal Visit for premature withdrawals)

    		 Close Top of page
    End point title
    		 Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Systemic Domain Sub-Score at Last Visit (Week 34 for completers or the Withdrawal Visit for premature withdrawals)
    End point description
    The Inflammatory Bowel Disease Questionnaire (IBDQ) Systemic Domain Sub-Score is the sum of 8 responses, each ranging from 0 to 7, thus the Sub-Score ranges from 0 to 56; a higher score indicating a better quality of life.
    End point type
    Secondary
    End point timeframe
    Week 0 and Last Visit (Week 34 relative to the start of the 6-week double-blind main study (NCT00291668) for completers or the Withdrawal Visit for premature withdrawals). 'Week 34' is 26 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    11
    6
    5
    Units: score on a scale
    arithmetic mean (standard deviation)
        mean (standard deviation)
    4.2 ( 4.1 )
    3.2 ( 4.4 )
    5.4 ( 2.1 )
    No statistical analyses for this end point

    Secondary: Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Emotional Domain Sub-Score at Week 8

    		 Close Top of page
    End point title
    		 Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Emotional Domain Sub-Score at Week 8
    End point description
    The IBDQ Emotional Domain Sub-Score is the sum of 8 responses, each ranging from 0 to 7, thus the Sub-Score ranges from 0 to 56; a higher score indicating a better quality of life.
    End point type
    Secondary
    End point timeframe
    Week 0 and Week 8 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 8' is the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    12
    7
    7
    Units: score on a scale
    arithmetic mean (standard deviation)
        mean (standard deviation)
    -0.3 ( 6.1 )
    2.1 ( 2.3 )
    0.4 ( 6.7 )
    No statistical analyses for this end point

    Secondary: Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Emotional Domain Sub-Score at Week 10

    		 Close Top of page
    End point title
    		 Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Emotional Domain Sub-Score at Week 10
    End point description
    The IBDQ Emotional Domain Sub-Score is the sum of 8 responses, each ranging from 0 to 7, thus the Sub-Score ranges from 0 to 56; a higher score indicating a better quality of life.
    End point type
    Secondary
    End point timeframe
    Week 0 and Week 10 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 10' is 2 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    12
    7
    7
    Units: score on a scale
    arithmetic mean (standard deviation)
        mean (standard deviation)
    3.3 ( 4.7 )
    4.4 ( 9.7 )
    4.3 ( 5.9 )
    No statistical analyses for this end point

    Secondary: Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Emotional Domain Sub-Score at Week 12

    		 Close Top of page
    End point title
    		 Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Emotional Domain Sub-Score at Week 12
    End point description
    The IBDQ Emotional Domain Sub-Score is the sum of 8 responses, each ranging from 0 to 7, thus the Sub-Score ranges from 0 to 56; a higher score indicating a better quality of life.
    End point type
    Secondary
    End point timeframe
    Week 0 and Week 12 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 12' is 4 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    12
    7
    7
    Units: score on a scale
    arithmetic mean (standard deviation)
        mean (standard deviation)
    2.5 ( 5.5 )
    7 ( 13.8 )
    5.3 ( 6.5 )
    No statistical analyses for this end point

    Secondary: Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Emotional Domain Sub-Score at Week 14

    		 Close Top of page
    End point title
    		 Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Emotional Domain Sub-Score at Week 14
    End point description
    The IBDQ Emotional Domain Sub-Score is the sum of 8 responses, each ranging from 0 to 7, thus the Sub-Score ranges from 0 to 56; a higher score indicating a better quality of life.
    End point type
    Secondary
    End point timeframe
    Week 0 and Week 14 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 14' is 6 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    12
    7
    7
    Units: score on a scale
    arithmetic mean (standard deviation)
        mean (standard deviation)
    3.8 ( 4 )
    7.1 ( 10.3 )
    6.7 ( 8 )
    No statistical analyses for this end point

    Secondary: Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Emotional Domain Sub-Score at Week 16

    		 Close Top of page
    End point title
    		 Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Emotional Domain Sub-Score at Week 16
    End point description
    The IBDQ Emotional Domain Sub-Score is the sum of 8 responses, each ranging from 0 to 7, thus the Sub-Score ranges from 0 to 56; a higher score indicating a better quality of life.
    End point type
    Secondary
    End point timeframe
    Week 0 and Week 16 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 16' is 8 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    12
    7
    7
    Units: score on a scale
    arithmetic mean (standard deviation)
        mean (standard deviation)
    2.5 ( 5.8 )
    3 ( 6.2 )
    6 ( 8.1 )
    No statistical analyses for this end point

    Secondary: Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Emotional Domain Sub-Score at Week 20

    		 Close Top of page
    End point title
    		 Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Emotional Domain Sub-Score at Week 20
    End point description
    The IBDQ Emotional Domain Sub-Score is the sum of 8 responses, each ranging from 0 to 7, thus the Sub-Score ranges from 0 to 56; a higher score indicating a better quality of life.
    End point type
    Secondary
    End point timeframe
    Week 0 and Week 20 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 20' is 12 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    11
    7
    7
    Units: score on a scale
    arithmetic mean (standard deviation)
        mean (standard deviation)
    1.9 ( 6.5 )
    3.4 ( 10.7 )
    3.6 ( 6.9 )
    No statistical analyses for this end point

    Secondary: Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Emotional Domain Sub-Score at Week 24

    		 Close Top of page
    End point title
    		 Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Emotional Domain Sub-Score at Week 24
    End point description
    The IBDQ Emotional Domain Sub-Score is the sum of 8 responses, each ranging from 0 to 7, thus the Sub-Score ranges from 0 to 56; a higher score indicating a better quality of life.
    End point type
    Secondary
    End point timeframe
    Week 0 and Week 24 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 24' is 16 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    9
    7
    7
    Units: score on a scale
    arithmetic mean (standard deviation)
        mean (standard deviation)
    2.1 ( 5.9 )
    1.6 ( 5.7 )
    6.1 ( 7.4 )
    No statistical analyses for this end point

    Secondary: Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Emotional Domain Sub-Score at Week 28

    		 Close Top of page
    End point title
    		 Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Emotional Domain Sub-Score at Week 28
    End point description
    The IBDQ Emotional Domain Sub-Score is the sum of 8 responses, each ranging from 0 to 7, thus the Sub-Score ranges from 0 to 56; a higher score indicating a better quality of life.
    End point type
    Secondary
    End point timeframe
    Week 0 and Week 28 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 28' is 20 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    9
    7
    7
    Units: score on a scale
    arithmetic mean (standard deviation)
        mean (standard deviation)
    4.3 ( 5.8 )
    1.1 ( 8 )
    3.6 ( 7.4 )
    No statistical analyses for this end point

    Secondary: Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Emotional Domain Sub-Score at Week 32

    		 Close Top of page
    End point title
    		 Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Emotional Domain Sub-Score at Week 32
    End point description
    The IBDQ Emotional Domain Sub-Score is the sum of 8 responses, each ranging from 0 to 7, thus the Sub-Score ranges from 0 to 56; a higher score indicating a better quality of life.
    End point type
    Secondary
    End point timeframe
    Week 0 and Week 32 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 32' is 24 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    8
    5
    6
    Units: score on a scale
    arithmetic mean (standard deviation)
        mean (standard deviation)
    2.9 ( 5.7 )
    1.8 ( 6.1 )
    7.7 ( 9.5 )
    No statistical analyses for this end point

    Secondary: Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Emotional Domain Sub-Score at Week 34

    		 Close Top of page
    End point title
    		 Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Emotional Domain Sub-Score at Week 34
    End point description
    The IBDQ Emotional Domain Sub-Score is the sum of 8 responses, each ranging from 0 to 7, thus the Sub-Score ranges from 0 to 56; a higher score indicating a better quality of life.
    End point type
    Secondary
    End point timeframe
    Week 0 and Week 34 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 34' is 26 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    8
    5
    5
    Units: score on a scale
    arithmetic mean (standard deviation)
        mean (standard deviation)
    5.6 ( 6.7 )
    0 ( 8.6 )
    6.4 ( 10.9 )
    No statistical analyses for this end point

    Secondary: Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Emotional Domain Sub-Score at Last Visit (Week 34 for completers or the Withdrawal Visit for premature withdrawals)

    		 Close Top of page
    End point title
    		 Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Emotional Domain Sub-Score at Last Visit (Week 34 for completers or the Withdrawal Visit for premature withdrawals)
    End point description
    The Inflammatory Bowel Disease Questionnaire (IBDQ) Emotional Domain Sub-Score is the sum of 8 responses, each ranging from 0 to 7, thus the Sub-Score ranges from 0 to 56; a higher score indicating a better quality of life.
    End point type
    Secondary
    End point timeframe
    Week 0 and Last Visit (Week 34 relative to the start of the 6-week double-blind main study (NCT00291668) for completers or the Withdrawal Visit for premature withdrawals). 'Week 34' is 26 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    11
    6
    5
    Units: score on a scale
    arithmetic mean (standard deviation)
        mean (standard deviation)
    3.5 ( 7.1 )
    0.7 ( 7.9 )
    6.4 ( 10.9 )
    No statistical analyses for this end point

    Secondary: Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Social Domain Sub-Score at Week 8

    		 Close Top of page
    End point title
    		 Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Social Domain Sub-Score at Week 8
    End point description
    The IBDQ Social Domain Sub-Score is the sum of 8 responses, each ranging from 0 to 7, thus the Sub-Score ranges from 0 to 56; a higher score indicating a better quality of life.
    End point type
    Secondary
    End point timeframe
    Week 0 and Week 8 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 8' is the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    11
    7
    7
    Units: score on a scale
    arithmetic mean (standard deviation)
        mean (standard deviation)
    1.3 ( 3.6 )
    0 ( 2.4 )
    0.7 ( 3.7 )
    No statistical analyses for this end point

    Secondary: Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Social Domain Sub-Score at Week 10

    		 Close Top of page
    End point title
    		 Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Social Domain Sub-Score at Week 10
    End point description
    The IBDQ Social Domain Sub-Score is the sum of 8 responses, each ranging from 0 to 7, thus the Sub-Score ranges from 0 to 56; a higher score indicating a better quality of life.
    End point type
    Secondary
    End point timeframe
    Week 0 and Week 10 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 10' is 2 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    11
    7
    7
    Units: score on a scale
    arithmetic mean (standard deviation)
        mean (standard deviation)
    2.5 ( 3 )
    2.1 ( 4.7 )
    1.1 ( 3.4 )
    No statistical analyses for this end point

    Secondary: Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Social Domain Sub-Score at Week 12

    		 Close Top of page
    End point title
    		 Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Social Domain Sub-Score at Week 12
    End point description
    The IBDQ Social Domain Sub-Score is the sum of 8 responses, each ranging from 0 to 7, thus the Sub-Score ranges from 0 to 56; a higher score indicating a better quality of life.
    End point type
    Secondary
    End point timeframe
    Week 0 and Week 12 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 12' is 4 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    11
    7
    7
    Units: score on a scale
    arithmetic mean (standard deviation)
        mean (standard deviation)
    3 ( 3.1 )
    2.6 ( 5.1 )
    2.3 ( 4 )
    No statistical analyses for this end point

    Secondary: Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Social Domain Sub-Score at Week 14

    		 Close Top of page
    End point title
    		 Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Social Domain Sub-Score at Week 14
    End point description
    The IBDQ Social Domain Sub-Score is the sum of 8 responses, each ranging from 0 to 7, thus the Sub-Score ranges from 0 to 56; a higher score indicating a better quality of life.
    End point type
    Secondary
    End point timeframe
    Week 0 and Week 14 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 14' is 6 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    11
    7
    7
    Units: score on a scale
    arithmetic mean (standard deviation)
        mean (standard deviation)
    2.8 ( 2.6 )
    2.7 ( 3.4 )
    4 ( 2 )
    No statistical analyses for this end point

    Secondary: Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Social Domain Sub-Score at Week 16

    		 Close Top of page
    End point title
    		 Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Social Domain Sub-Score at Week 16
    End point description
    The IBDQ Social Domain Sub-Score is the sum of 8 responses, each ranging from 0 to 7, thus the Sub-Score ranges from 0 to 56; a higher score indicating a better quality of life.
    End point type
    Secondary
    End point timeframe
    Week 0 and Week 16 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 16' is 8 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    11
    7
    7
    Units: score on a scale
    arithmetic mean (standard deviation)
        mean (standard deviation)
    2.5 ( 2.1 )
    0 ( 3.9 )
    2.4 ( 2.1 )
    No statistical analyses for this end point

    Secondary: Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Social Domain Sub-Score at Week 20

    		 Close Top of page
    End point title
    		 Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Social Domain Sub-Score at Week 20
    End point description
    The IBDQ Social Domain Sub-Score is the sum of 8 responses, each ranging from 0 to 7, thus the Sub-Score ranges from 0 to 56; a higher score indicating a better quality of life.
    End point type
    Secondary
    End point timeframe
    Week 0 and Week 20 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 20' is 12 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    10
    7
    7
    Units: score on a scale
    arithmetic mean (standard deviation)
        mean (standard deviation)
    2.8 ( 2.3 )
    1.6 ( 3 )
    3.6 ( 2.3 )
    No statistical analyses for this end point

    Secondary: Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Social Domain Sub-Score at Week 24

    		 Close Top of page
    End point title
    		 Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Social Domain Sub-Score at Week 24
    End point description
    The IBDQ Social Domain Sub-Score is the sum of 8 responses, each ranging from 0 to 7, thus the Sub-Score ranges from 0 to 56; a higher score indicating a better quality of life.
    End point type
    Secondary
    End point timeframe
    Week 0 and Week 24 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 24' is 16 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    8
    7
    7
    Units: score on a scale
    arithmetic mean (standard deviation)
        mean (standard deviation)
    1.8 ( 2.7 )
    -0.9 ( 4.9 )
    2.6 ( 2.1 )
    No statistical analyses for this end point

    Secondary: Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Social Domain Sub-Score at Week 28

    		 Close Top of page
    End point title
    		 Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Social Domain Sub-Score at Week 28
    End point description
    The IBDQ Social Domain Sub-Score is the sum of 8 responses, each ranging from 0 to 7, thus the Sub-Score ranges from 0 to 56; a higher score indicating a better quality of life.
    End point type
    Secondary
    End point timeframe
    Week 0 and Week 28 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 28' is 20 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    8
    7
    7
    Units: score on a scale
    arithmetic mean (standard deviation)
        mean (standard deviation)
    2.1 ( 2.7 )
    -1 ( 4.6 )
    2.4 ( 3.1 )
    No statistical analyses for this end point

    Secondary: Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Social Domain Sub-Score at Week 32

    		 Close Top of page
    End point title
    		 Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Social Domain Sub-Score at Week 32
    End point description
    The IBDQ Social Domain Sub-Score is the sum of 8 responses, each ranging from 0 to 7, thus the Sub-Score ranges from 0 to 56; a higher score indicating a better quality of life.
    End point type
    Secondary
    End point timeframe
    Week 0 and Week 32 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 32' is 24 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    7
    5
    6
    Units: score on a scale
    arithmetic mean (standard deviation)
        mean (standard deviation)
    1.3 ( 3.4 )
    -0.6 ( 2.9 )
    3.3 ( 2.4 )
    No statistical analyses for this end point

    Secondary: Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Social Domain Sub-Score at Week 34

    		 Close Top of page
    End point title
    		 Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Social Domain Sub-Score at Week 34
    End point description
    The IBDQ Social Domain Sub-Score is the sum of 8 responses, each ranging from 0 to 7, thus the Sub-Score ranges from 0 to 56; a higher score indicating a better quality of life.
    End point type
    Secondary
    End point timeframe
    Week 0 and Week 34 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 34' is 26 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    7
    5
    5
    Units: score on a scale
    arithmetic mean (standard deviation)
        mean (standard deviation)
    3 ( 3 )
    0 ( 3.4 )
    3 ( 3.1 )
    No statistical analyses for this end point

    Secondary: Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Social Domain Sub-Score at Last Visit (Week 34 for completers or the Withdrawal Visit for premature withdrawals)

    		 Close Top of page
    End point title
    		 Change from Week 0 in Inflammatory Bowel Disease Questionnaire (IBDQ) Social Domain Sub-Score at Last Visit (Week 34 for completers or the Withdrawal Visit for premature withdrawals)
    End point description
    The Inflammatory Bowel Disease Questionnaire (IBDQ) Social Domain Sub-Score is the sum of 8 responses, each ranging from 0 to 7, thus the Sub-Score ranges from 0 to 56; a higher score indicating a better quality of life.
    End point type
    Secondary
    End point timeframe
    Week 0 and Last Visit (Week 34 relative to the start of the 6-week double-blind main study (NCT00291668) for completers or the Withdrawal Visit for premature withdrawals). 'Week 34' is 26 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    10
    6
    5
    Units: score on a scale
    arithmetic mean (standard deviation)
        mean (standard deviation)
    1.7 ( 3.4 )
    -1.3 ( 4.5 )
    3 ( 3.1 )
    No statistical analyses for this end point

    Secondary: C-Reactive Protein (CRP) Level at Week 0

    		 Close Top of page
    End point title
    		 C-Reactive Protein (CRP) Level at Week 0
    End point description
    End point type
    Secondary
    End point timeframe
    Week 0 (relative to the start of the 6-week double-blind main study (N00291668)). 'Week 0' is the Baseline visit in the double-blind main study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    12
    7
    7
    Units: mg/L
    geometric mean (full range (min-max))
        geometric mean (full range)
    19.58 (4 to 60)
    14.97 (10 to 25)
    26.45 (16 to 50)
    No statistical analyses for this end point

    Secondary: C-Reactive Protein (CRP) Level at Week 8

    		 Close Top of page
    End point title
    		 C-Reactive Protein (CRP) Level at Week 8
    End point description
    End point type
    Secondary
    End point timeframe
    Week 8 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 8' is the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    12
    7
    7
    Units: mg/L
    geometric mean (full range (min-max))
        geometric mean (full range)
    22.06 (8 to 76)
    11.91 (4 to 41)
    16.7 (1 to 55)
    No statistical analyses for this end point

    Secondary: C-Reactive Protein (CRP) Level at Week 10

    		 Close Top of page
    End point title
    		 C-Reactive Protein (CRP) Level at Week 10
    End point description
    End point type
    Secondary
    End point timeframe
    Week 10 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 10' is 2 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    12
    7
    7
    Units: mg/L
    geometric mean (full range (min-max))
        geometric mean (full range)
    7.76 (2 to 40)
    5.62 (3 to 13)
    12.01 (1 to 34)
    No statistical analyses for this end point

    Secondary: C-Reactive Protein (CRP) Level at Week 12

    		 Close Top of page
    End point title
    		 C-Reactive Protein (CRP) Level at Week 12
    End point description
    End point type
    Secondary
    End point timeframe
    Week 12 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 12' is 4 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    12
    7
    7
    Units: mg/L
    geometric mean (full range (min-max))
        geometric mean (full range)
    7.82 (2 to 31)
    7.06 (3 to 14)
    13.39 (1 to 54)
    No statistical analyses for this end point

    Secondary: C-Reactive Protein (CRP) Level at Week 14

    		 Close Top of page
    End point title
    		 C-Reactive Protein (CRP) Level at Week 14
    End point description
    End point type
    Secondary
    End point timeframe
    Week 14 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 14' is 6 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    12
    7
    7
    Units: mg/L
    geometric mean (full range (min-max))
        geometric mean (full range)
    9.57 (2 to 32)
    6.32 (4 to 14)
    15.3 (1 to 41)
    No statistical analyses for this end point

    Secondary: C-Reactive Protein (CRP) Level at Week 16

    		 Close Top of page
    End point title
    		 C-Reactive Protein (CRP) Level at Week 16
    End point description
    End point type
    Secondary
    End point timeframe
    Week 16 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 16' is 8 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    12
    7
    7
    Units: mg/L
    geometric mean (full range (min-max))
        geometric mean (full range)
    12.54 (3 to 35)
    12.23 (3 to 45)
    15.1 (1 to 36)
    No statistical analyses for this end point

    Secondary: C-Reactive Protein (CRP) Level at Week 20

    		 Close Top of page
    End point title
    		 C-Reactive Protein (CRP) Level at Week 20
    End point description
    End point type
    Secondary
    End point timeframe
    Week 20 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 20' is 12 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    11
    7
    7
    Units: mg/L
    geometric mean (full range (min-max))
        geometric mean (full range)
    12.27 (1 to 74)
    13.24 (4 to 50)
    14.99 (1 to 53)
    No statistical analyses for this end point

    Secondary: C-Reactive Protein (CRP) Level at Week 24

    		 Close Top of page
    End point title
    		 C-Reactive Protein (CRP) Level at Week 24
    End point description
    End point type
    Secondary
    End point timeframe
    Week 24 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 24' is 16 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    9
    7
    7
    Units: mg/L
    geometric mean (full range (min-max))
        geometric mean (full range)
    9.11 (1 to 45)
    14.16 (4 to 33)
    15.7 (1 to 38)
    No statistical analyses for this end point

    Secondary: C-Reactive Protein (CRP) Level at Week 28

    		 Close Top of page
    End point title
    		 C-Reactive Protein (CRP) Level at Week 28
    End point description
    End point type
    Secondary
    End point timeframe
    Week 28 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 28' is 20 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    9
    7
    7
    Units: mg/L
    geometric mean (full range (min-max))
        geometric mean (full range)
    8.79 (1 to 24)
    14.25 (4 to 40)
    26.81 (0 to 33)
    No statistical analyses for this end point

    Secondary: C-Reactive Protein (CRP) Level at Week 32

    		 Close Top of page
    End point title
    		 C-Reactive Protein (CRP) Level at Week 32
    End point description
    End point type
    Secondary
    End point timeframe
    Week 32 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 32' is 24 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    8
    5
    6
    Units: mg/L
    geometric mean (full range (min-max))
        geometric mean (full range)
    15.28 (3 to 45)
    10.27 (2 to 24)
    16.71 (1 to 48)
    No statistical analyses for this end point

    Secondary: C-Reactive Protein (CRP) Level at Week 34

    		 Close Top of page
    End point title
    		 C-Reactive Protein (CRP) Level at Week 34
    End point description
    End point type
    Secondary
    End point timeframe
    Week 34 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 34' is 26 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    8
    5
    5
    Units: mg/L
    geometric mean (full range (min-max))
        geometric mean (full range)
    9.19 (1 to 40)
    6.23 (2 to 16)
    23.52 (0 to 81)
    No statistical analyses for this end point

    Secondary: C-Reactive Protein (CRP) Level at Last Visit (Week 34 for completers or the Withdrawal Visit for premature withdrawals)

    		 Close Top of page
    End point title
    		 C-Reactive Protein (CRP) Level at Last Visit (Week 34 for completers or the Withdrawal Visit for premature withdrawals)
    End point description
    End point type
    Secondary
    End point timeframe
    Last Visit (Week 34 relative to the start of the 6-week double-blind main study (NCT00291668) for completers or the Withdrawal Visit for premature withdrawals). 'Week 34' is 26 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    11
    6
    5
    Units: mg/L
    geometric mean (full range (min-max))
        geometric mean (full range)
    11.25 (1 to 75)
    8.46 (2 to 39)
    23.52 (0 to 81)
    No statistical analyses for this end point

    Secondary: Ratio of C-Reactive Protein (CRP) level at Week 8 to CRP level at Week 0

    		 Close Top of page
    End point title
    		 Ratio of C-Reactive Protein (CRP) level at Week 8 to CRP level at Week 0
    End point description
    The ratio is calculated as the C-Reactive Protein (CRP) Level at Week 8 divided by the CRP Level at Week 0
    End point type
    Secondary
    End point timeframe
    Week 0 and Week 8 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 8' is the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    12
    7
    7
    Units: ratio
    geometric mean (full range (min-max))
        geometric mean (full range)
    1.13 (0.4 to 4.3)
    0.8 (0.2 to 4.1)
    0.63 (0 to 3.4)
    No statistical analyses for this end point

    Secondary: Ratio of C-Reactive Protein (CRP) level at Week 10 to CRP level at Week 0

    		 Close Top of page
    End point title
    		 Ratio of C-Reactive Protein (CRP) level at Week 10 to CRP level at Week 0
    End point description
    The ratio is calculated as the C-Reactive Protein (CRP) Level at Week 10 divided by the CRP Level at Week 0
    End point type
    Secondary
    End point timeframe
    Week 0 and Week 10 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 10' is 2 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    12
    7
    7
    Units: ratio
    geometric mean (full range (min-max))
        geometric mean (full range)
    0.4 (0.1 to 1.5)
    0.38 (0.1 to 1.2)
    0.45 (0 to 2)
    No statistical analyses for this end point

    Secondary: Ratio of C-Reactive Protein (CRP) level at Week 12 to CRP level at Week 0

    		 Close Top of page
    End point title
    		 Ratio of C-Reactive Protein (CRP) level at Week 12 to CRP level at Week 0
    End point description
    The ratio is calculated as the C-Reactive Protein (CRP) Level at Week 12 divided by the CRP Level at Week 0
    End point type
    Secondary
    End point timeframe
    Week 0 and Week 12 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 12' is 4 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    12
    7
    7
    Units: ratio
    geometric mean (full range (min-max))
        geometric mean (full range)
    0.4 (0.1 to 2)
    0.47 (0.2 to 1.1)
    0.51 (0 to 3.2)
    No statistical analyses for this end point

    Secondary: Ratio of C-Reactive Protein (CRP) level at Week 14 to CRP level at Week 0

    		 Close Top of page
    End point title
    		 Ratio of C-Reactive Protein (CRP) level at Week 14 to CRP level at Week 0
    End point description
    The ratio is calculated as the C-Reactive Protein (CRP) Level at Week 14 divided by the CRP Level at Week 0
    End point type
    Secondary
    End point timeframe
    Week 0 and Week 14 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 14' is 6 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    12
    7
    7
    Units: ratio
    geometric mean (full range (min-max))
        geometric mean (full range)
    0.49 (0.1 to 5)
    0.42 (0.2 to 1)
    0.58 (0 to 2.4)
    No statistical analyses for this end point

    Secondary: Ratio of C-Reactive Protein (CRP) level at Week 16 to CRP level at Week 0

    		 Close Top of page
    End point title
    		 Ratio of C-Reactive Protein (CRP) level at Week 16 to CRP level at Week 0
    End point description
    The ratio is calculated as the C-Reactive Protein (CRP) Level at Week 16 divided by the CRP Level at Week 0
    End point type
    Secondary
    End point timeframe
    Week 0 and Week 16 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 16' is 8 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    12
    7
    7
    Units: ratio
    geometric mean (full range (min-max))
        geometric mean (full range)
    0.64 (0.1 to 5.3)
    0.82 (0.3 to 4.1)
    0.57 (0 to 2.3)
    No statistical analyses for this end point

    Secondary: Ratio of C-Reactive Protein (CRP) level at Week 20 to CRP level at Week 0

    		 Close Top of page
    End point title
    		 Ratio of C-Reactive Protein (CRP) level at Week 20 to CRP level at Week 0
    End point description
    The ratio is calculated as the C-Reactive Protein (CRP) Level at Week 20 divided by the CRP Level at Week 0
    End point type
    Secondary
    End point timeframe
    Week 0 and Week 20 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 20' is 12 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    11
    7
    7
    Units: ratio
    geometric mean (full range (min-max))
        geometric mean (full range)
    0.64 (0 to 5.5)
    0.88 (0.3 to 4.5)
    0.57 (0 to 3.1)
    No statistical analyses for this end point

    Secondary: Ratio of C-Reactive Protein (CRP) level at Week 24 to CRP level at Week 0

    		 Close Top of page
    End point title
    		 Ratio of C-Reactive Protein (CRP) level at Week 24 to CRP level at Week 0
    End point description
    The ratio is calculated as the C-Reactive Protein (CRP) Level at Week 24 divided by the CRP Level at Week 0
    End point type
    Secondary
    End point timeframe
    Week 0 and Week 24 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 24' is 16 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    9
    7
    7
    Units: ratio
    geometric mean (full range (min-max))
        geometric mean (full range)
    0.48 (0 to 3.5)
    0.95 (0.4 to 2.4)
    0.59 (0 to 1.7)
    No statistical analyses for this end point

    Secondary: Ratio of C-Reactive Protein (CRP) level at Week 28 to CRP level at Week 0

    		 Close Top of page
    End point title
    		 Ratio of C-Reactive Protein (CRP) level at Week 28 to CRP level at Week 0
    End point description
    The ratio is calculated as the C-Reactive Protein (CRP) Level at Week 28 divided by the CRP Level at Week 0
    End point type
    Secondary
    End point timeframe
    Week 0 and Week 28 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 28' is 20 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    9
    7
    7
    Units: ratio
    geometric mean (full range (min-max))
        geometric mean (full range)
    0.46 (0 to 2.8)
    0.95 (0.2 to 2.7)
    1.06 (0 to 2.1)
    No statistical analyses for this end point

    Secondary: Ratio of C-Reactive Protein (CRP) level at Week 32 to CRP level at Week 0

    		 Close Top of page
    End point title
    		 Ratio of C-Reactive Protein (CRP) level at Week 32 to CRP level at Week 0
    End point description
    The ratio is calculated as the C-Reactive Protein (CRP) Level at Week 32 divided by the CRP Level at Week 0
    End point type
    Secondary
    End point timeframe
    Week 0 and Week 32 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 32' is 24 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    8
    5
    6
    Units: ratio
    geometric mean (full range (min-max))
        geometric mean (full range)
    0.9 (0.1 to 4.6)
    0.64 (0.2 to 1.2)
    0.62 (0 to 2.8)
    No statistical analyses for this end point

    Secondary: Ratio of C-Reactive Protein (CRP) level at Week 34 to CRP level at Week 0

    		 Close Top of page
    End point title
    		 Ratio of C-Reactive Protein (CRP) level at Week 34 to CRP level at Week 0
    End point description
    The ratio is calculated as the C-Reactive Protein (CRP) Level at Week 34 divided by the CRP Level at Week 0
    End point type
    Secondary
    End point timeframe
    Week 0 and Week 34 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 34' is 26 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    8
    5
    5
    Units: ratio
    geometric mean (full range (min-max))
        geometric mean (full range)
    0.54 (0 to 2.8)
    0.39 (0.2 to 1.6)
    1.07 (0 to 3.5)
    No statistical analyses for this end point

    Secondary: Ratio of C-Reactive Protein (CRP) level at Last Visit (Week 34 for completers or the Withdrawal Visit for premature withdrawals) to CRP level at Week 0

    		 Close Top of page
    End point title
    		 Ratio of C-Reactive Protein (CRP) level at Last Visit (Week 34 for completers or the Withdrawal Visit for premature withdrawals) to CRP level at Week 0
    End point description
    The ratio is calculated as the C-Reactive Protein (CRP) Level at Last Visit (Week 34 for completers or the Withdrawal Visit for premature withdrawals)divided by the CRP Level at Week 0
    End point type
    Secondary
    End point timeframe
    Week 0 and Last Visit (Week 34 relative to the start of the 6-week double-blind main study (NCT00291668) for completers or the Withdrawal Visit for premature withdrawals). 'Week 34' is 26 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    11
    6
    5
    Units: ratio
    geometric mean (full range (min-max))
        geometric mean (full range)
    0.59 (0 to 2.8)
    0.54 (0.2 to 2.8)
    1.07 (0 to 3.5)
    No statistical analyses for this end point

    Secondary: Percentage of subjects achieving a reduction in Crohn’s Disease Activity Index (CDAI) score of ≥70 points from Week 0 at Week 8

    		 Close Top of page
    End point title
    		 Percentage of subjects achieving a reduction in Crohn’s Disease Activity Index (CDAI) score of ≥70 points from Week 0 at Week 8
    End point description
    70-point responders are subjects achieving a reduction in Crohn’s Disease Activity Index (CDAI) score of ≥70 points from Week 0. CDAI is used to quantify the symptoms of subjects with Crohn's disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
    End point type
    Secondary
    End point timeframe
    Week 0 and Week 8 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 8' is the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    12
    7
    7
    Units: percentage of subjects
    number (not applicable)
        Percentage of 70-point responders
    33.3
    28.6
    42.9
        Percentage of 70-point non-responders
    66.7
    71.4
    57.1
    No statistical analyses for this end point

    Secondary: Percentage of subjects achieving a reduction in Crohn’s Disease Activity Index (CDAI) score of ≥70 points from Week 0 at Week 10

    		 Close Top of page
    End point title
    		 Percentage of subjects achieving a reduction in Crohn’s Disease Activity Index (CDAI) score of ≥70 points from Week 0 at Week 10
    End point description
    70-point responders are subjects achieving a reduction in Crohn’s Disease Activity Index (CDAI) score of ≥70 points from Week 0. CDAI is used to quantify the symptoms of subjects with Crohn's disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
    End point type
    Secondary
    End point timeframe
    Week 0 and Week 10 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 10' is 2 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    12
    7
    7
    Units: percentage of subjects
    number (not applicable)
        Percentage of 70-point responders
    66.7
    85.7
    100
        Percentage of 70-point non-responders
    33.3
    14.3
    0
    No statistical analyses for this end point

    Secondary: Percentage of subjects achieving a reduction in Crohn’s Disease Activity Index (CDAI) score of ≥70 points from Week 0 at Week 12

    		 Close Top of page
    End point title
    		 Percentage of subjects achieving a reduction in Crohn’s Disease Activity Index (CDAI) score of ≥70 points from Week 0 at Week 12
    End point description
    70-point responders are subjects achieving a reduction in Crohn’s Disease Activity Index (CDAI) score of ≥70 points from Week 0. CDAI is used to quantify the symptoms of subjects with Crohn's disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
    End point type
    Secondary
    End point timeframe
    Week 0 and Week 12 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 12' is 4 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    12
    7
    7
    Units: percentage of subjects
    number (not applicable)
        Percentage of 70-point responders
    75
    71.4
    85.7
        Percentage of 70-point non-responders
    25
    28.6
    14.3
    No statistical analyses for this end point

    Secondary: Percentage of subjects achieving a reduction in Crohn’s Disease Activity Index (CDAI) score of ≥70 points from Week 0 at Week 14

    		 Close Top of page
    End point title
    		 Percentage of subjects achieving a reduction in Crohn’s Disease Activity Index (CDAI) score of ≥70 points from Week 0 at Week 14
    End point description
    70-point responders are subjects achieving a reduction in Crohn’s Disease Activity Index (CDAI) score of ≥70 points from Week 0. CDAI is used to quantify the symptoms of subjects with Crohn's disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
    End point type
    Secondary
    End point timeframe
    Week 0 and Week 14 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 14' is 6 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    12
    7
    7
    Units: percentage of subjects
    number (not applicable)
        Percentage of 70-point responders
    100
    100
    100
        Percentage of 70-point non-responders
    0
    0
    0
    No statistical analyses for this end point

    Secondary: Percentage of subjects achieving a reduction in Crohn’s Disease Activity Index (CDAI) score of ≥70 points from Week 0 at Week 16

    		 Close Top of page
    End point title
    		 Percentage of subjects achieving a reduction in Crohn’s Disease Activity Index (CDAI) score of ≥70 points from Week 0 at Week 16
    End point description
    70-point responders are subjects achieving a reduction in Crohn’s Disease Activity Index (CDAI) score of ≥70 points from Week 0. CDAI is used to quantify the symptoms of subjects with Crohn's disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
    End point type
    Secondary
    End point timeframe
    Week 0 and Week 16 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 16' is 8 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    12
    7
    7
    Units: percentage of subjects
    number (not applicable)
        Percentage of 70-point responders
    83.3
    57.1
    100
        Percentage of 70-point non-responders
    16.7
    42.9
    0
    No statistical analyses for this end point

    Secondary: Percentage of subjects achieving a reduction in Crohn’s Disease Activity Index (CDAI) score of ≥70 points from Week 0 at Week 20

    		 Close Top of page
    End point title
    		 Percentage of subjects achieving a reduction in Crohn’s Disease Activity Index (CDAI) score of ≥70 points from Week 0 at Week 20
    End point description
    70-point responders are subjects achieving a reduction in Crohn’s Disease Activity Index (CDAI) score of ≥70 points from Week 0. CDAI is used to quantify the symptoms of subjects with Crohn's disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
    End point type
    Secondary
    End point timeframe
    Week 0 and Week 20 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 20' is 12 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    12
    7
    7
    Units: percentage of subjects
    number (not applicable)
        Percentage of 70-point responders
    75
    71.4
    85.7
        Percentage of 70-point non-responders
    25
    28.6
    14.3
    No statistical analyses for this end point

    Secondary: Percentage of subjects achieving a reduction in Crohn’s Disease Activity Index (CDAI) score of ≥70 points from Week 0 at Week 24

    		 Close Top of page
    End point title
    		 Percentage of subjects achieving a reduction in Crohn’s Disease Activity Index (CDAI) score of ≥70 points from Week 0 at Week 24
    End point description
    70-point responders are subjects achieving a reduction in Crohn’s Disease Activity Index (CDAI) score of ≥70 points from Week 0. CDAI is used to quantify the symptoms of subjects with Crohn's disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
    End point type
    Secondary
    End point timeframe
    Week 0 and Week 24 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 24' is 16 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    12
    7
    7
    Units: percentage of subjects
    number (not applicable)
        Percentage of 70-point responders
    50
    71.4
    100
        Percentage of 70-point non-responders
    50
    28.6
    0
    No statistical analyses for this end point

    Secondary: Percentage of subjects achieving a reduction in Crohn’s Disease Activity Index (CDAI) score of ≥70 points from Week 0 at Week 28

    		 Close Top of page
    End point title
    		 Percentage of subjects achieving a reduction in Crohn’s Disease Activity Index (CDAI) score of ≥70 points from Week 0 at Week 28
    End point description
    70-point responders are subjects achieving a reduction in Crohn’s Disease Activity Index (CDAI) score of ≥70 points from Week 0. CDAI is used to quantify the symptoms of subjects with Crohn's disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
    End point type
    Secondary
    End point timeframe
    Week 0 and Week 28 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 28' is 20 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    12
    7
    7
    Units: percentage of subjects
    number (not applicable)
        Percentage of 70-point responders
    58.3
    71.4
    85.7
        Percentage of 70-point non-responders
    41.7
    28.6
    14.3
    No statistical analyses for this end point

    Secondary: Percentage of subjects achieving a reduction in Crohn’s Disease Activity Index (CDAI) score of ≥70 points from Week 0 at Week 32

    		 Close Top of page
    End point title
    		 Percentage of subjects achieving a reduction in Crohn’s Disease Activity Index (CDAI) score of ≥70 points from Week 0 at Week 32
    End point description
    70-point responders are subjects achieving a reduction in Crohn’s Disease Activity Index (CDAI) score of ≥70 points from Week 0. CDAI is used to quantify the symptoms of subjects with Crohn's disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
    End point type
    Secondary
    End point timeframe
    Week 0 and Week 32 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 32' is 24 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    12
    7
    7
    Units: percentage of subjects
    number (not applicable)
        Percentage of 70-point responders
    41.7
    57.1
    57.1
        Percentage of 70-point non-responders
    58.3
    42.9
    42.9
    No statistical analyses for this end point

    Secondary: Percentage of subjects achieving a reduction in Crohn’s Disease Activity Index (CDAI) score of ≥70 points from Week 0 at Week 34

    		 Close Top of page
    End point title
    		 Percentage of subjects achieving a reduction in Crohn’s Disease Activity Index (CDAI) score of ≥70 points from Week 0 at Week 34
    End point description
    70-point responders are subjects achieving a reduction in Crohn’s Disease Activity Index (CDAI) score of ≥70 points from Week 0. CDAI is used to quantify the symptoms of subjects with Crohn's disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
    End point type
    Secondary
    End point timeframe
    Week 0 and Week 34 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 34' is 26 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    12
    7
    7
    Units: percentage of subjects
    number (not applicable)
        Percentage of 70-point responders
    66.7
    42.9
    42.9
        Percentage of 70-point non-responders
    33.3
    57.1
    57.1
    No statistical analyses for this end point

    Secondary: Percentage of subjects achieving a reduction in Crohn’s Disease Activity Index (CDAI) score of ≥70 points from Week 0 at Last Visit (Week 34 for completers or the Withdrawal Visit for premature withdrawals)

    		 Close Top of page
    End point title
    		 Percentage of subjects achieving a reduction in Crohn’s Disease Activity Index (CDAI) score of ≥70 points from Week 0 at Last Visit (Week 34 for completers or the Withdrawal Visit for premature withdrawals)
    End point description
    70-point responders are subjects achieving a reduction in Crohn’s Disease Activity Index (CDAI) score of ≥70 points from Week 0. CDAI is used to quantify the symptoms of subjects with Crohn's disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
    End point type
    Secondary
    End point timeframe
    Week 0 and Last Visit (Week 34 relative to the start of the 6-week double-blind main study (NCT00291668) for completers or the Withdrawal Visit for premature withdrawals). 'Week 34' is 26 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    12
    7
    7
    Units: percentage of subjects
    number (not applicable)
        Percentage of 70-point responders
    66.7
    42.9
    42.9
        Percentage of 70-point non-responders
    33.3
    57.1
    57.1
    No statistical analyses for this end point

    Post-hoc: Number of subjects with disease progression

    		 Close Top of page
    End point title
    		 Number of subjects with disease progression
    End point description
    Disease progression is defined as: - an increase from Week 14 of ≥100 points in Crohn’s Disease Activity Index (CDAI) score and CDAI>175 points for at least 2 consecutive visits, - use of rescue therapy, or, - subject withdrawal from the study.
    End point type
    Post-hoc
    End point timeframe
    Week 14 to Week 34 (relative to the start of the 6-week double-blind main study (NCT00291668)). 'Week 14' is the visit at which response to re-induction is assessed and 'Week 34' is 26 weeks after the first visit in this extension study.
    End point values
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg
    Number of subjects analysed
    12
    7
    7
    Units: subjects
        Number of subjects
    1
    1
    1
    No statistical analyses for this end point

    Adverse events

    		 Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    Adverse event data summarized in the first four columns were collected from the day after the end of the double-blind main study up to and including 12 weeks following the last dose received in this extension study for each subject (i.e., up to 36 weeks).
    Adverse event reporting additional description
    For the fifth column, 'Total 2', this presents the data summarized in 'Total 1' PLUS adverse event data from the double-blind main study for subjects who received certolizumab pegol (CZP) in the main study and then entered this extension study (i.e., up to 44 weeks).
    Assessment type
    		 Non-systematic
    Dictionary used for adverse event reporting
    Dictionary name
    		 MedDRA
    Dictionary version
    9.0
    Reporting groups
    Reporting group title
    CZP 400 mg / Placebo
    Reporting group description
    		 Certolizumab pegol (CZP) 400 mg (3 doses 2-weekly then 5 doses 4-weekly) in this extension study / Placebo (3 doses 2-weekly) in the 6-week double-blind main study (2014-004399-42)

    Reporting group title
    CZP 400 mg / CZP 200 mg
    Reporting group description
    		 Certolizumab pegol (CZP) 400 mg (3 doses 2-weekly then 5 doses 4-weekly) in this extension study / Certolizumab pegol (CZP) 200 mg (3 doses 2-weekly) in the 6-week double-blind main study (2014-004399-42)

    Reporting group title
    CZP 400 mg / CZP 400 mg
    Reporting group description
    		 Certolizumab pegol (CZP) 400 mg (3 doses 2-weekly then 5 doses 4-weekly) in this extension study / Certolizumab pegol (CZP) 400 mg (3 doses 2-weekly) in the 6-week double-blind main study (2014-004399-42)

    Reporting group title
    Total 1 (This extension study only)
    Reporting group description
    		 This includes all adverse event data collected in this extension study for all 46 subjects who entered this extension study.

    Serious adverse events
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg Total 1 (This extension study only)
    Total subjects affected by serious adverse events
         subjects affected / exposed
    1 / 18 (5.56%)
    3 / 13 (23.08%)
    4 / 15 (26.67%)
    8 / 46 (17.39%)
         number of deaths (all causes)
    0
    0
    0
    0
         number of deaths resulting from adverse events
    0
    0
    0
    0
    Gastrointestinal disorders
    Crohn's disease
         subjects affected / exposed
    0 / 18 (0.00%)
    1 / 13 (7.69%)
    3 / 15 (20.00%)
    4 / 46 (8.70%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    2 / 3
    2 / 4
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Psychiatric disorders
    Psychotic disorder
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 13 (0.00%)
    1 / 15 (6.67%)
    1 / 46 (2.17%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    1 / 1
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Suicide attempt
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 13 (0.00%)
    1 / 15 (6.67%)
    1 / 46 (2.17%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    1 / 1
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Musculoskeletal and connective tissue disorders
    Osteomalacia
         subjects affected / exposed
    0 / 18 (0.00%)
    1 / 13 (7.69%)
    0 / 15 (0.00%)
    1 / 46 (2.17%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Infections and infestations
    Perianal abscess
         subjects affected / exposed
    1 / 18 (5.56%)
    0 / 13 (0.00%)
    0 / 15 (0.00%)
    1 / 46 (2.17%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pulmonary tuberculosis
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 13 (0.00%)
    1 / 15 (6.67%)
    1 / 46 (2.17%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    1 / 1
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Metabolism and nutrition disorders
    Electrolyte imbalance
         subjects affected / exposed
    0 / 18 (0.00%)
    1 / 13 (7.69%)
    0 / 15 (0.00%)
    1 / 46 (2.17%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Tetany
         subjects affected / exposed
    0 / 18 (0.00%)
    1 / 13 (7.69%)
    0 / 15 (0.00%)
    1 / 46 (2.17%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    		 CZP 400 mg / Placebo CZP 400 mg / CZP 200 mg CZP 400 mg / CZP 400 mg Total 1 (This extension study only)
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    15 / 18 (83.33%)
    10 / 13 (76.92%)
    13 / 15 (86.67%)
    38 / 46 (82.61%)
    General disorders and administration site conditions
    Chest pain
         subjects affected / exposed
    1 / 18 (5.56%)
    0 / 13 (0.00%)
    0 / 15 (0.00%)
    1 / 46 (2.17%)
         occurrences all number
    1
    0
    0
    1
    Injection site eyrthema
         subjects affected / exposed
    1 / 18 (5.56%)
    0 / 13 (0.00%)
    0 / 15 (0.00%)
    1 / 46 (2.17%)
         occurrences all number
    1
    0
    0
    1
    Malaise
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 13 (0.00%)
    1 / 15 (6.67%)
    1 / 46 (2.17%)
         occurrences all number
    0
    0
    1
    1
    Pyrexia
         subjects affected / exposed
    2 / 18 (11.11%)
    6 / 13 (46.15%)
    3 / 15 (20.00%)
    11 / 46 (23.91%)
         occurrences all number
    2
    9
    3
    14
    Swelling
         subjects affected / exposed
    1 / 18 (5.56%)
    0 / 13 (0.00%)
    0 / 15 (0.00%)
    1 / 46 (2.17%)
         occurrences all number
    1
    0
    0
    1
    Immune system disorders
    Anaphylactic reaction
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 13 (0.00%)
    1 / 15 (6.67%)
    1 / 46 (2.17%)
         occurrences all number
    0
    0
    1
    1
    Respiratory, thoracic and mediastinal disorders
    Cough
         subjects affected / exposed
    0 / 18 (0.00%)
    1 / 13 (7.69%)
    0 / 15 (0.00%)
    1 / 46 (2.17%)
         occurrences all number
    0
    1
    0
    1
    Dyspnoea
         subjects affected / exposed
    1 / 18 (5.56%)
    0 / 13 (0.00%)
    0 / 15 (0.00%)
    1 / 46 (2.17%)
         occurrences all number
    1
    0
    0
    1
    Pneumothorax
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 13 (0.00%)
    1 / 15 (6.67%)
    1 / 46 (2.17%)
         occurrences all number
    0
    0
    1
    1
    Rhinitis allergic
         subjects affected / exposed
    0 / 18 (0.00%)
    2 / 13 (15.38%)
    0 / 15 (0.00%)
    2 / 46 (4.35%)
         occurrences all number
    0
    2
    0
    2
    Upper respiratory tract inflammation
         subjects affected / exposed
    0 / 18 (0.00%)
    1 / 13 (7.69%)
    0 / 15 (0.00%)
    1 / 46 (2.17%)
         occurrences all number
    0
    1
    0
    1
    Psychiatric disorders
    Depressive symptom
         subjects affected / exposed
    0 / 18 (0.00%)
    1 / 13 (7.69%)
    0 / 15 (0.00%)
    1 / 46 (2.17%)
         occurrences all number
    0
    1
    0
    1
    Emotional distress
         subjects affected / exposed
    1 / 18 (5.56%)
    0 / 13 (0.00%)
    0 / 15 (0.00%)
    1 / 46 (2.17%)
         occurrences all number
    1
    0
    0
    1
    Initial insomnia
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 13 (0.00%)
    1 / 15 (6.67%)
    1 / 46 (2.17%)
         occurrences all number
    0
    0
    1
    1
    Insomnia
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 13 (0.00%)
    1 / 15 (6.67%)
    1 / 46 (2.17%)
         occurrences all number
    0
    0
    1
    1
    Investigations
    Blood calcium decreased
         subjects affected / exposed
    0 / 18 (0.00%)
    1 / 13 (7.69%)
    0 / 15 (0.00%)
    1 / 46 (2.17%)
         occurrences all number
    0
    1
    0
    1
    Blood potassium decreased
         subjects affected / exposed
    0 / 18 (0.00%)
    1 / 13 (7.69%)
    0 / 15 (0.00%)
    1 / 46 (2.17%)
         occurrences all number
    0
    1
    0
    1
    DNA antibody positive
         subjects affected / exposed
    1 / 18 (5.56%)
    0 / 13 (0.00%)
    1 / 15 (6.67%)
    2 / 46 (4.35%)
         occurrences all number
    1
    0
    1
    2
    Haemoglobin decreased
         subjects affected / exposed
    1 / 18 (5.56%)
    0 / 13 (0.00%)
    0 / 15 (0.00%)
    1 / 46 (2.17%)
         occurrences all number
    1
    0
    0
    1
    White blood cell count decreased
         subjects affected / exposed
    1 / 18 (5.56%)
    0 / 13 (0.00%)
    0 / 15 (0.00%)
    1 / 46 (2.17%)
         occurrences all number
    2
    0
    0
    2
    Injury, poisoning and procedural complications
    Contusion
         subjects affected / exposed
    0 / 18 (0.00%)
    2 / 13 (15.38%)
    0 / 15 (0.00%)
    2 / 46 (4.35%)
         occurrences all number
    0
    3
    0
    3
    Excoriation
         subjects affected / exposed
    1 / 18 (5.56%)
    0 / 13 (0.00%)
    0 / 15 (0.00%)
    1 / 46 (2.17%)
         occurrences all number
    1
    0
    0
    1
    Fall
         subjects affected / exposed
    1 / 18 (5.56%)
    0 / 13 (0.00%)
    0 / 15 (0.00%)
    1 / 46 (2.17%)
         occurrences all number
    1
    0
    0
    1
    Foot fracture
         subjects affected / exposed
    0 / 18 (0.00%)
    1 / 13 (7.69%)
    0 / 15 (0.00%)
    1 / 46 (2.17%)
         occurrences all number
    0
    1
    0
    1
    Rib fracture
         subjects affected / exposed
    0 / 18 (0.00%)
    1 / 13 (7.69%)
    0 / 15 (0.00%)
    1 / 46 (2.17%)
         occurrences all number
    0
    1
    0
    1
    Cardiac disorders
    Palpitations
         subjects affected / exposed
    1 / 18 (5.56%)
    0 / 13 (0.00%)
    1 / 15 (6.67%)
    2 / 46 (4.35%)
         occurrences all number
    1
    0
    1
    2
    Tachycardia
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 13 (0.00%)
    1 / 15 (6.67%)
    1 / 46 (2.17%)
         occurrences all number
    0
    0
    1
    1
    Nervous system disorders
    Dizziness postural
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 13 (0.00%)
    1 / 15 (6.67%)
    1 / 46 (2.17%)
         occurrences all number
    0
    0
    1
    1
    Headache
         subjects affected / exposed
    1 / 18 (5.56%)
    0 / 13 (0.00%)
    0 / 15 (0.00%)
    1 / 46 (2.17%)
         occurrences all number
    1
    0
    0
    1
    Hypoaesthesia
         subjects affected / exposed
    1 / 18 (5.56%)
    2 / 13 (15.38%)
    0 / 15 (0.00%)
    3 / 46 (6.52%)
         occurrences all number
    1
    2
    0
    3
    Loss of consciousness
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 13 (0.00%)
    1 / 15 (6.67%)
    1 / 46 (2.17%)
         occurrences all number
    0
    0
    1
    1
    Blood and lymphatic system disorders
    Anaemia
         subjects affected / exposed
    1 / 18 (5.56%)
    0 / 13 (0.00%)
    0 / 15 (0.00%)
    1 / 46 (2.17%)
         occurrences all number
    1
    0
    0
    1
    Ear and labyrinth disorders
    Ear discomfort
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 13 (0.00%)
    1 / 15 (6.67%)
    1 / 46 (2.17%)
         occurrences all number
    0
    0
    1
    1
    Eye disorders
    Ocular hyperaemia
         subjects affected / exposed
    1 / 18 (5.56%)
    0 / 13 (0.00%)
    0 / 15 (0.00%)
    1 / 46 (2.17%)
         occurrences all number
    1
    0
    0
    1
    Gastrointestinal disorders
    Abdominal pain lower
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 13 (0.00%)
    1 / 15 (6.67%)
    1 / 46 (2.17%)
         occurrences all number
    0
    0
    1
    1
    Abdominal pain upper
         subjects affected / exposed
    0 / 18 (0.00%)
    1 / 13 (7.69%)
    1 / 15 (6.67%)
    2 / 46 (4.35%)
         occurrences all number
    0
    1
    1
    2
    Crohn's disease
         subjects affected / exposed
    1 / 18 (5.56%)
    0 / 13 (0.00%)
    0 / 15 (0.00%)
    1 / 46 (2.17%)
         occurrences all number
    1
    0
    0
    1
    Duodenal ulcer
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 13 (0.00%)
    1 / 15 (6.67%)
    1 / 46 (2.17%)
         occurrences all number
    0
    0
    1
    1
    Gastroduodenitis
         subjects affected / exposed
    0 / 18 (0.00%)
    1 / 13 (7.69%)
    0 / 15 (0.00%)
    1 / 46 (2.17%)
         occurrences all number
    0
    1
    0
    1
    Nausea
         subjects affected / exposed
    1 / 18 (5.56%)
    0 / 13 (0.00%)
    2 / 15 (13.33%)
    3 / 46 (6.52%)
         occurrences all number
    1
    0
    2
    3
    Periodontitis
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 13 (0.00%)
    1 / 15 (6.67%)
    1 / 46 (2.17%)
         occurrences all number
    0
    0
    2
    2
    Salivary gland disorder
         subjects affected / exposed
    0 / 18 (0.00%)
    1 / 13 (7.69%)
    0 / 15 (0.00%)
    1 / 46 (2.17%)
         occurrences all number
    0
    1
    0
    1
    Stomatitis
         subjects affected / exposed
    1 / 18 (5.56%)
    0 / 13 (0.00%)
    0 / 15 (0.00%)
    1 / 46 (2.17%)
         occurrences all number
    1
    0
    0
    1
    Toothache
         subjects affected / exposed
    0 / 18 (0.00%)
    1 / 13 (7.69%)
    1 / 15 (6.67%)
    2 / 46 (4.35%)
         occurrences all number
    0
    1
    1
    2
    Vomiting
         subjects affected / exposed
    1 / 18 (5.56%)
    1 / 13 (7.69%)
    1 / 15 (6.67%)
    3 / 46 (6.52%)
         occurrences all number
    1
    1
    1
    3
    Hepatobiliary disorders
    Hepatic function abnormal
         subjects affected / exposed
    1 / 18 (5.56%)
    0 / 13 (0.00%)
    1 / 15 (6.67%)
    2 / 46 (4.35%)
         occurrences all number
    1
    0
    1
    2
    Skin and subcutaneous tissue disorders
    Alopecia
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 13 (0.00%)
    1 / 15 (6.67%)
    1 / 46 (2.17%)
         occurrences all number
    0
    0
    1
    1
    Dermatitis atopic
         subjects affected / exposed
    0 / 18 (0.00%)
    1 / 13 (7.69%)
    0 / 15 (0.00%)
    1 / 46 (2.17%)
         occurrences all number
    0
    1
    0
    1
    Dry skin
         subjects affected / exposed
    0 / 18 (0.00%)
    1 / 13 (7.69%)
    0 / 15 (0.00%)
    1 / 46 (2.17%)
         occurrences all number
    0
    1
    0
    1
    Eczema
         subjects affected / exposed
    1 / 18 (5.56%)
    0 / 13 (0.00%)
    1 / 15 (6.67%)
    2 / 46 (4.35%)
         occurrences all number
    1
    0
    1
    2
    Eczema asteatotic
         subjects affected / exposed
    1 / 18 (5.56%)
    0 / 13 (0.00%)
    0 / 15 (0.00%)
    1 / 46 (2.17%)
         occurrences all number
    1
    0
    0
    1
    Pruritus
         subjects affected / exposed
    1 / 18 (5.56%)
    0 / 13 (0.00%)
    0 / 15 (0.00%)
    1 / 46 (2.17%)
         occurrences all number
    1
    0
    0
    1
    Musculoskeletal and connective tissue disorders
    Muscle tightness
         subjects affected / exposed
    0 / 18 (0.00%)
    1 / 13 (7.69%)
    0 / 15 (0.00%)
    1 / 46 (2.17%)
         occurrences all number
    0
    2
    0
    2
    Infections and infestations
    Cystitis
         subjects affected / exposed
    1 / 18 (5.56%)
    1 / 13 (7.69%)
    0 / 15 (0.00%)
    2 / 46 (4.35%)
         occurrences all number
    1
    1
    0
    2
    Dental caries
         subjects affected / exposed
    0 / 18 (0.00%)
    1 / 13 (7.69%)
    0 / 15 (0.00%)
    1 / 46 (2.17%)
         occurrences all number
    0
    1
    0
    1
    Herpes zoster
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 13 (0.00%)
    1 / 15 (6.67%)
    1 / 46 (2.17%)
         occurrences all number
    0
    0
    1
    1
    Influenza
         subjects affected / exposed
    0 / 18 (0.00%)
    1 / 13 (7.69%)
    0 / 15 (0.00%)
    1 / 46 (2.17%)
         occurrences all number
    0
    1
    0
    1
    Nasopharyngitis
         subjects affected / exposed
    10 / 18 (55.56%)
    5 / 13 (38.46%)
    6 / 15 (40.00%)
    21 / 46 (45.65%)
         occurrences all number
    15
    8
    7
    30
    Paronychia
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 13 (0.00%)
    1 / 15 (6.67%)
    1 / 46 (2.17%)
         occurrences all number
    0
    0
    1
    1
    Perianal abscess
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 13 (0.00%)
    1 / 15 (6.67%)
    1 / 46 (2.17%)
         occurrences all number
    0
    0
    2
    2
    Pharyngitis
         subjects affected / exposed
    2 / 18 (11.11%)
    0 / 13 (0.00%)
    1 / 15 (6.67%)
    3 / 46 (6.52%)
         occurrences all number
    2
    0
    1
    3
    Pulpitis dental
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 13 (0.00%)
    1 / 15 (6.67%)
    1 / 46 (2.17%)
         occurrences all number
    0
    0
    1
    1
    Urinary tract infection
         subjects affected / exposed
    1 / 18 (5.56%)
    0 / 13 (0.00%)
    0 / 15 (0.00%)
    1 / 46 (2.17%)
         occurrences all number
    1
    0
    0
    1
    Metabolism and nutrition disorders
    Anorexia
         subjects affected / exposed
    1 / 18 (5.56%)
    0 / 13 (0.00%)
    0 / 15 (0.00%)
    1 / 46 (2.17%)
         occurrences all number
    1
    0
    0
    1
    Electrolyte imbalance
         subjects affected / exposed
    0 / 18 (0.00%)
    1 / 13 (7.69%)
    0 / 15 (0.00%)
    1 / 46 (2.17%)
         occurrences all number
    0
    1
    0
    1
    Hypoalbuminaemia
         subjects affected / exposed
    0 / 18 (0.00%)
    1 / 13 (7.69%)
    1 / 15 (6.67%)
    2 / 46 (4.35%)
         occurrences all number
    0
    2
    1
    3
    Vitamin D deficiency
         subjects affected / exposed
    0 / 18 (0.00%)
    1 / 13 (7.69%)
    0 / 15 (0.00%)
    1 / 46 (2.17%)
         occurrences all number
    0
    1
    0
    1

    More information

    		 Close Top of page

    Substantial protocol amendments (globally)
    Were there any global substantial amendments to the protocol? No

    Interruptions (globally)
    Were there any global interruptions to the trial? No

    Limitations and caveats
    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    Due to the small number of subjects in this study, the percentages of subjects with adverse events may be misleading.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 05:57:55 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA